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Abstract  
  
Autotaxin   is   an   extracellular   enzyme   that   generates   lysophosphatidic   acid  
(LPA).  LPA  binds  up  to  six  different  cell  surface  G  protein-­‐‑coupled  receptors  
to  initiate  signaling  resulting  in  cell  survival,   invasion  and  angiogenesis.  For  
this  reason  autotaxin  has  emerged  as  a  therapeutic  target  in  several  different  
malignancies. 
   
I  have  used  immunohistochemistry  to  explore  the  expression  of  autotaxin  and  
its  correlation  with  clinico-­‐‑pathological  variables  in  bladder  and  renal  cancer. 
   
I   show   that   in   bladder   cancer,   tumours   from  patients  with  muscle   invasive  
disease   were   significantly   more   likely   to   show   strong  autotaxin   expression  
than   were   those   tumours   from   patients   without   evidence   of   muscle  
involvement  (p=0.009).  This  observation  is  not  only  consistent  with  the  known  
functions  of  autotaxin/LPA  in  promoting  tumour  invasion,  but  suggests  that  
the   potential   use   autotaxin   inhibitors   in   preventing   bladder   cancer  
progression  warrants  further  investigation. 
   
Although  I  failed  to  detect  autotaxin  expression  in  the  tumour  cells  of  patients  
with  renal  cancer,  I  did  observe  high-­‐‑level  expression  of  autotaxin  on  the  
tumour-­‐‑associated  vasculature,  which  in  many  cases  was  not  apparent  in  
blood  vessels  of  matched  normal  renal  tissues.  This  points  to  an  important  
role  for  autotaxin  in  renal  cancer-­‐‑associated  angiogenesis  and  suggests  a  
potential  role  for  autotaxin  inhibition  as  an  anti-­‐‑angiogenesis  therapy.     
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Introduction  
1.1  Bladder  Cancer  
  
Bladder  cancer  is  the  fourth  most  common  malignancy  in  males  and  twelfth  
most  common  in  females  in  the  UK.  It  has  an  incidence  of  10,000  new  cases  
and  5,000  deaths  per  year  (www.statistics.gov.uk,  Cancer  Research  UK).      
Approximately  70%  of  patients  present  with  disease  that  is  confined  to  the  
mucosa  (stage  Ta,  CIS),  or  submucosal  (stage  T1).  These  cases  are  described  as  
non-­‐‑muscle  invasive  bladder  cancer  (NMIBC)  and  have  excellent  long  term  
survival  but  are  characterized  by  frequent  recurrences  (Messing  et  al.,  1995)  
The  remaining  30%  of  cases  are  described  as  muscle-­‐‑invasive  bladder  cancer  
(MIBC)  (EAU  2012).    This  type  of  bladder  cancer  has  a  high  mortality  rate  
within  2  years  (Prout  and  Marshall,  1956).  
Rates  of  morbidity  and  mortality  in  the  UK  are  similar  to  those  in  Europe  and  
North  America.    
Bladder  cancer  surveillance  can  be  life  long  and  presents  the  healthcare  
system  with  a  huge  financial  burden  not  to  mention  the  psychological  burden  
imposed  on  the  patient.    For  example,  Stenzl  et  al  (2008)  estimated  that  the  
cost  per  patient  from  diagnosis  to  death  was  $96,000  to  $187,000  and  that  the  
total  cost  within  the  United  States  in  2001  was  $3.7  billion.  
Therefore  there  is  a  desperate  need  to  identify  causative  factors,  at  a  
molecular  level,  that  could  be  used  as  therapeutic  targets  to  improve  
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1.1.1  Pathology  of  bladder  cancer  
Greater  than  90%  of  all  bladder  cancers  are  transitional  cell  carcinoma  (TCC)  
(Lopez-­‐‑Beltran,  2008).    This  group  can  further  be  divided  into  papillary,  
sessile  and  carcinoma  in  situ  (CIS).    CIS  is  presumed  to  be  a  histologically  
recognizable  precursor  of  invasive  carcinoma.  
Approximately  5%  are  squamous  cell  carcinoma  and  are  associated  with  
chronic  irritation  of  the  bladder  epithelium.  The  majority  of  these  cases  are  
linked  to  chronic  schistosomiasis  infection  but  other  associations  are  the  
presence  of  a  long-­‐‑term  catheter  and  bladder  calculi.  
Less  than  2%  are  adenocarcinoma  of  the  bladder.  There  are  3  types  including  
papillary,  polypoid  and  nodular.  They  are  associated  with  chronic  infection;  
glandular  cystitis  is  frequently  associated  with  this  lesion,  or  bladder  
extrophy.  
  
1.1.2  Grade  and  Stage  of  bladder  cancer  
According  to  the  1973  WHO  grading  transitional  call  carcinoma  is  graded  into  
well  (G1),  moderately  (G2),  and  poorly  (G3)  differentiated  tumours.    However  
this  has  been  superseded  by  the  2004  WHO  grading  which  grades  TCC  into  
urothelial  papilloma,  papillary  urothelial  neoplasm  of  low  malignant  
potential  (PUNLMP),  low-­‐‑grade  papillary  urothelial  carcinoma  and  high-­‐‑
grade  papillary  urothelial  carcinoma.  
The  papilloma  is  composed  of  a  delicate  fibrovascular  core  covered  by  normal  
urothelium.  A  PUNLMP  is  defined  as  a  papillary  fibrovascular  growth  
covered  by  proliferated  urothelium  exceeding  normal  thickness.    PUNLMP  
have  a  low  risk  of  progression,  but  they  are  not  completely  benign  and  tend  
to  recur.    The  low-­‐‑grade  papillary  urothelial  carcinoma  group  includes  all  
former  grade  1  (WHO  1973)  cases  and  some  grade  2  cases.  
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The  2004  WHO  classification  system  is  recommended  as  it  stratifies  according  
to  risk  potential.  However  the  1973  WHO  classification  system  is  still  very  
much  in  use  today  as  many  find  it  a  simpler  system  to  use.  
  
Table  1.1:  WHO  Grading  in  1973  and  in  2004  (Epstein  et  al.  (1998)  &  Sauter  
et  al.  (2004))  
1973  WHO  Grading  
Urothelial  Papilloma  
Grade  1:  well  differentiated  
Grade  2:  moderately  differentiated  
Grade  3:  poorly  differentiated  
  
2004  WHO  grading  system  (papillary  lesions)  
Urothelial  papilloma  (completely  benign  lesion)  
Papillary  urothelial  neoplasm  of  low  malignant  potential  (PUNLMP)  
Low-­‐‑grade  (LG)  papillary  urothelial  carcinoma  
High-­‐‑grade  (HG)  papillary  urothelial  carcinoma  
  
For  staging,  TNM  (tumour,  lymph  nodes  and  metastases)  2010  is  used  for  
bladder  cancer  as  can  be  seen  illustrated  below.    pTa  includes  tumours  that  
have  not  invaded  or  breached  the  basement  membrane.  pT1  includes  those  
tumours  that  have  breached  the  basement  membrane,  pT2  includes  those  that  
have  invaded  the  muscularis  mucosa,  pT3  includes  those  invading  the  
perivesical  tissue  and  pT4  includes  those  invading  neighbouring  organs  
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Table  1.2:  TNM  Classification  of  Urinary  Bladder  Cancer    
(Sobin  et  al.  2009)  
T-­‐‑  Primary  Tumour  
Tx    Primary  tumour  cannot  be  assessed  
T0  No  evidence  of  primary  tumour  
Ta  Non-­‐‑invasive  papillary  carcinoma  
Tis  Carcinoma  in  situ:  “flat  tumour”  
T1  Tumour  invades  subepithelial  connective  tissue  or  lamina  propria  
T2  Tumour  invades  muscle:  
T2a  Tumour  invades  superficial  muscle  (inner  half)  
T2b  Tumour  invades  deep  muscle  (outer  half)  
T3  Tumour  invades  perivesical  tissue:  
T3a  Microscopically  
T3b  Macroscopically  
T4  Tumour  invades  any  of  the  following:  prostate  stroma,  seminal  vesicles,  
uterus,  vagina,  pelvic  wall,  abdominal  wall  
T4a  Tumour  invades  prostate  stroma,  seminal  vesicles,  uterus  or  vagina  
T4b  Tumour  invades  pelvic  wall  or  abdominal  wall  
N-­‐‑  Regional  Lymph  Nodes  
Nx  Regional  lymph  nodes  cannot  be  assessed  
N0  No  regional  lymph  nodes  metastases  
N1  Metastases  in  a  single  lymph  node  in  the  true  pelvis  (hypogastric,  
obturator,  external  iliac,  or  presacral)  
N2  Metastases  in  multiple  lymph  nodes  in  the  true  pelvis  (hypogastric,  
obturator,  external  iliac,  or  presacral)  
N3  Metastases  in  common  iliac  lymph  node(s)  
M-­‐‑  Distant  Metastases  
M0  No  distant  metastasis  
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M1  Distant  metastasis  
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1.1.3  Epidemiology  of  bladder  cancer  –  Incidence  and  Mortality  
In  the  United  Kingdom  (UK)  bladder  cancer  is  the  seventh  most  common  
cancer  (2011),  accounting  for  3%  of  all  new  cases.    It  is  the  fourth  most  
common  cancer  in  males  (4%  of  male  total),  whilst  it  is  the  12th  most  common  
cancer  in  females  (2%  of  female  total).    In  2011,  there  were  10,399  new  cases  of  
bladder  cancer  in  the  UK,  7452  (72%)  in  men  and  2947  (28%)  in  women,  
giving  a  male:  female  ratio  of  approximately  2.5:1  (Cancer  Research  UK,  
2015).  
Crude  incidence  rates  show  that  there  are  24  new  bladder  cancer  cases  for  
every  100,000  males  in  the  UK,  and  9  for  every  100,000  females.  
Bladder  cancer  incidence  is  strongly  related  to  age  with  the  highest  incidence  
rates  being  in  those  above  60  years  of  age  (www.cancerresearchuk.org).  
In  the  UK,  in  2010,  the  lifetime  risk  of  developing  bladder  cancer  was  1  in  40  
for  men  and  1  in  100  for  women.  
In  Europe,  bladder  cancer  is  the  5th  most  common  cancer  with  more  than  
151,000  new  cases  diagnosed  in  2012  (4%  of  the  total).  Worldwide,  it  is  the  9th  
most  common  cancer,  with  around  429,800  new  cases  diagnosed  in  2012  (3%  
of  the  total).  
Age  standardized  mortality  rates  globally  vary  from  2-­‐‑10  per  100,000  per  year  
for  men  and  0.5-­‐‑4  per  100,000  per  year  for  women.  
  
1.1.4  Bladder  cancer  risk  factors  
There  are  several  well-­‐‑established  risk  factors  for  bladder  cancer.    
Firstly,  tobacco  smoking  is  thought  to  be  responsible  for  50-­‐‑65%  of  male  cases  
and  20-­‐‑30%  of  female  cases  (Lokeshwar  et  al.  2005).    Incidence  of  bladder  
cancer  has  been  found  to  be  directly  related  to  duration  of  smoking  and  the  
number  of  cigarettes  smoked  per  day  (Stenzl  et  al.  2010).    The  risk  is  also  
higher  for  those  smoking  from  a  young  age  and  those  exposed  to  tobacco  
during  childhood  (May  et  al.  2003).  Furthermore,  there  was  a  significant  
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reduction  in  risk  in  those  who  stopped  smoking,  40%  reduction  within  1-­‐‑4  
years  of  stopping  and  60%  reduction  after  25  years  (Stenzl  et  al.  2010).  
  
The  second  most  important  risk  factor  is  occupational  exposure  to  chemicals.  
These  cases  account  for  20-­‐‑25%  of  bladder  cancer  cases  (EAU,  2012).    
Individuals  working  in  industries  that  use  rubbers,  paint,  dyes  and  chemicals  
are  most  at  risk.  
  
There  have  been  reports  of  increased  rates  of  secondary  bladder  malignancies  
after  external  beam  radiation  therapy  (ERBT)  for  gynaecological  
malignancies,  with  relative  risks  of  2  to  4  (Chrouser  et  al.  2006).    
Some  believe  there  is  an  association  between  dietary  factors  and  bladder  
cancer  however  no  causal  relationship  has  been  reported  (EAU  Guidelines  
2015).    The  EPIC  study  is  a  multi-­‐‑centre  cohort  study  examining  the  
association  between  diet,  environmental  and  lifestyle  factors  and  cancer.  So  
far  this  study  has  failed  to  report  any  links  between  red  meat,  fruit  and  
vegetable  consumption  and  fluid  intake  and  bladder  cancer.  However,  
recently  they  have  described  a  link  between  dietary  intake  of  flavonols  and  
ligans  and  risk  of  aggressive  bladder  cancer  (Zamora-­‐‑Ros  et  al.  2014)  
  
The  link  between  bladder  schistosomiasis    (bilharzia)  and  squamous  cell  
carcinoma  (SCC)  of  the  bladder  is  well  established.  However,  according  to  
recent  data  from  Egypt,  there  has  been  a  shift  from  SCC  to  transitional  cell  
carcinoma  (TCC).  This  is  thought  to  be  due  to  a  decline  in  the  detection  of  
bilharzia  eggs  in  the  urine  samples  due  to  better  control  of  the  disease  in  rural  
populations  (Grim  et  al.  2003,  Divrik  et  al.  2006).  
  
Separate  to  schistosomiasis,  chronic  urinary  tract  infection  has  been  linked  to  
muscle  invasive  bladder  cancer,  particularly  invasive  squamous  cell  
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carcinoma.    Several  case-­‐‑control  studies  have  demonstrated  a  direct  
association  between  bladder  cancer  and  urinary  tract  infections,  some  
reporting  as  much  as  a  twofold  increase  in  risk  of  bladder  cancer  in  patients  
suffering  from  recurrent  urinary  tract  infections  (EAU  Guidelines,  2012).  
  
Several  chemotherapy  agents  have  been  implicated  in  the  development  of  
muscle  invasive  bladder  cancer,  in  particular  cyclophosphamide,  (Payne  et  al.  
2013)  an  alkylating  agent  used  in  the  treatment  of  non-­‐‑neoplastic  diseases.  
The  metabolite  of  cyclophosphamide,  acrolein,  is  thought  to  be  responsible  
for  the  increased  incidence  of  bladder  cancer.  This  effect  was  found  to  be  
independent  of  the  association  of  haemorrhagic  cystitis  with  the  same  
treatment  (Kaldor  et  al.  1995,  Travis  et  al.  1995).      
  
An  association  between  upper  tract  tumours  and  bladder  cancer  has  been  
reported.  A  1.7%  -­‐‑  26%  incidence  of  non-­‐‑muscle  invasive  bladder  cancer  has  
been  reported  after  a  diagnosis  of  upper  urinary  tract  tumour  (EAU,  2012).      
In  a  retrospective  study  of  1529  patients  with  primary  non-­‐‑muscle  invasive  
bladder  carcinoma,  those  who  were  found  to  have  a  tumour  in  the  bladder  
trigone  were  almost  6  times  more  likely  to  develop  a  synchronous  tumour  in  
the  upper  urinary  tract  (Palou  et  al.  2005).    
  
Vaidya  et  al.  (2001)  performed  a  retrospective  study  of  patients  who  
underwent  radical  cystectomy  and  demonstrated  that  women  were  more  
likely  than  men  (85%  vs.  51%)  to  be  diagnosed  with  primary  muscle  invasive  
bladder  cancer.  They  also  suggested  that  women  were  more  likely  to  be  older  
at  diagnosis  and  that  delayed  diagnosis  was  more  likely  in  women  after  
haematuria  due  to  the  many  differential  diagnoses  such  as  urinary  tract  
infections  which  are  commoner  in  women  than  men  (Cardenas-­‐‑Turanzas  et  
al.  2006).  
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Hormonal  levels,  oestrogen  and  androgen,  have  also  been  deemed  
responsible  for  some  of  the  differences  in  gender  prevalence  of  bladder  cancer  
(McGrath  et  al.  2006,  Scosyrev  et  al.  2009,  Stenzl  et  al.  2010).  Post-­‐‑menopausal  
status  was  found  to  be  associated  with  an  increased  risk  of  bladder  cancer  
even  after  adjusting  for  smoking  status.      A  recent  study  of  Egyptian  women  
found  that  multiple  pregnancies  and  use  of  the  oral  contraceptive  pill  was  
associated  with  decreased  risk  of  developing  bladder  cancer  while  younger  
age  at  menopause  (<45  years)  was  associated  with  increased  risk  (Wolpert  et  
al.  2012).  
The  SEER  (surveillance,  epidemiology  and  end  results)  study  based  on  13,234  
cancer  cases  (including  female  breast,  colorectal,  prostate,  lung,  bronchus,  
uterine  cervix,  ovarian,  melanoma  and  urinary  bladder)  diagnosed  from  1979-­‐‑
2003,  showed  that  survival  from  diagnosis  was  associated  with  socioeconomic  
status  (health  income,  education,  income  and  poverty  status)  such  that  low  
socioeconomic  status  was  associated  with  reduced  survival  from  diagnosis  
compared  with  higher  socioeconomic  status  (Abdollah  et  al.  2013).    
They  also  found  that  when  comparing  black  and  white  racial  origin,  black  
racial  origin  had  unfavourable  prognoses  compared  with  white  racial  origin,  
even  after  adjustments  for  socioeconomic  status  were  made.    
  
1.1.5  Existing  treatments  for  bladder  cancer  
Treatment  of  bladder  cancer  differs  according  to  grade  and  stage  of  the  
tumour.    Generally,  non-­‐‑muscle  invasive  bladder  cancer  is  treated  with  an  
initial  resection  followed  by  intravesical  chemotherapy  (mitomycin  C)  and/or  
intravesical  Bacillus  Calmette-­‐‑Guerin  (BCG)  immunotherapy.    Muscle  
invasive  bladder  cancer  however,  is  treated  with  initial  resection  to  gain  
histology  but  is  then  followed  by  a  combination  of  either  surgery  with  or  
without  adjuvant  or  neo-­‐‑adjuvant  chemotherapy  or  radiotherapy  depending  
on  the  grade  and  stage.  The  aim  of  treatment  for  muscle  invasive  bladder  
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cancer  is  to  remove  all  loco-­‐‑regional  disease  including  the  primary  tumour  as  
well  as  regional  lymph  nodes.    Neo-­‐‑adjuvant  or  adjuvant  chemotherapy  may  
also  be  given  with  the  intention  of  targeting  occult  regional  nodes  and  
visceral  metastases  when  the  risk  is  high.  Radical  cystectomy  provides  good  
control  of  the  primary  tumour  as  it  involves  removal  of  the  entire  bladder,  
however  the  surrounding  structures  such  as  perivesical  tissue,  prostate,  and  
seminal  vesicles  in  men  and  ovaries,  uterus,  cervix  and  anterior  vagina  in  
women  are  also  removed.  
Chemotherapy  given  before  cystectomy,  known  as  neo-­‐‑adjuvant  
chemotherapy,  is  done  with  the  intention  of  treating  micro-­‐‑metastatic  disease  
present  at  diagnosis.  It  is  normally  considered  in  patients  with  stage  T2-­‐‑T4a  
muscle  invasive  disease.  
Adjuvant  chemotherapy  has  been  advised  for  patients  deemed  at  high  risk  of  
recurrence  in  an  attempt  to  delay  recurrence  and  prolong  survival.  The  
advantage  of  giving  chemotherapy  after  surgery  is  that  full  pathological  
staging  is  available.  
In  patients  wishing  to  preserve  sexual  function  and  therefore  quality  of  life  or  
those  not  fit  for  surgery  can  be  offered  a  bladder  preserving  approach  which  
consists  of  a  combination  of  chemotherapy  and  radiotherapy.  This  would  
only  be  appropriate  in  patients  with  solitary  T2  or  early  T2  tumours  less  than  
6cm  in  size,  no  tumour-­‐‑associated  hydronephrosis,  tumours  allowing  a  
visibly  complete  transurethral  resection  of  the  tumour,  invasive  tumours  in  
the  absence  of  carcinoma  in  situ,  and  renal  function  that  will  permit  
subsequent  chemotherapy  (Wein  et  al.  2012).  
  
1.1.6  Molecular  Biology  of  Bladder  Cancer  
Cancer  is  abnormal  and  unregulated  cell  growth  that  occurs  after  a  triggering  
event  that  results  in  cell  change.  Two  types  of  gene  have  been  associated  in  
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initiating  these  cancer-­‐‑forming  changes;  proto-­‐‑oncogenes  and  tumour  
suppressor  genes.  
Proto-­‐‑oncogenes  become  drivers  of  cancer  as  a  result  of  point  mutations  in  the  
genetic  code  that  result  in  unregulated  growth,  or  gene  amplification  or  
translocation,  both  of  which  increase  the  level  of  protein.  The  resultant  proto-­‐‑
oncogene  becomes  an  oncogene  that  can  promote  cancer  (Lengauer  et  al.  
1998).  
Tumour  suppressor  genes  normally  act  to  inhibit  cancer  formation,  however    
deletions  in  the  allele  or  frameshift  mutations  may  have  the  opposite  effect  
thereby  contributing  to  the  development  of  cancer.  
There  have  been  two  pathways  thought  to  be  involved  in  bladder  cancer  
formation.  The  first  is  from  normal  urothelium  to  low  grade  non-­‐‑invasive  and  
the  second  is  from  normal  urothelium  to  CIS  and  then  muscle  invasive  
disease.  A  third  pathway  has  now  been  proposed  involving  normal  
urothelium  to  hyperplasia/dysplasia  to  high-­‐‑grade  papillary  carcinoma  and  
then  to  muscle  invasive  disease  (Wein  et  al.  2012).    
Recognized  genetic  mutations  in  low-­‐‑grade  non-­‐‑muscle  invasive  disease  are  
alterations  in  the  fibroblast  growth  factor  receptor  3  (FGFR  3)  and  deletions  of  
chromosome  9q.    While  mutations  in  p53  and  RB  loss  are  associated  with  
high-­‐‑grade  aggressive  disease.  
The  conversion  of  normal  urothelium  to  dysplasia  is  associated  with  deletions  
in  chromosome  9  in  75%  of  cases,  abnormal  p53  in  50%  and  increased  cellular  
growth  in  all  cases  (Mallofre  et  al.  2003).    The  main  genetic  changes  separating  
non-­‐‑muscle  invasive  disease  from  muscle  invasive  are  high  FGFR-­‐‑3  and  low  
TP53  mutation  rates  and  genetic  instability  (Wein  et  al.  2012).  
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1.1.7  Bladder  Cancer  Prognosis  Programme  
The  Bladder  Cancer  Prognosis  Programme  (BCPP)  is  a  large  epidemiological  
prospective  longitudinal  cohort  study  of  all  patients  with  newly  diagnosed  
bladder  cancer  within  the  West  Midlands,  UK.    It  was  initiated  in  2005  by  the  
Cancer  Research  UK  Bladder  Cancer  Group,  based  at  the  University  of  
Birmingham  (UK).    
  
There  were  3  clear  objectives  of  the  BCPP.  First  to  assess  what  effect,  if  any,  
modifiable  lifestyle  factors  such  as  dietary  habits,  smoking,  fluid  intake  and  
environmental  exposures,  have  on  recurrence  and  progression  of  bladder  
cancer.      
It  also  considered  quality  of  life  variables  and  possible  associations  with  
recurrence  and  progression  of  bladder  cancer.      
The  role  of  molecular  biomarkers  in  predicting  bladder  cancer  recurrence  and  
progression  in  addition  to  investigating  whether  or  not  selenium  and  vitamin  
E  play  any  role  in  reducing  the  risk  of  bladder  cancer  recurrence  and  
progression  in  patients  with  non-­‐‑muscle  invasive  bladder  cancer,  are  among  
some  of  the  studies  that  have  arisen  out  of  the  BCPP  study.  
  
The  BCPP  bio-­‐‑bank  is  one  of  the  world’s  largest  and  most  detailed  collections  
and  comprises  fresh  frozen  bladder  cancer  tissues,  blood  and  urine.    Each  
sample  is  linked  to  over  a  thousand  variables,  relating  to  clinical,  
epidemiological  and  pathological  data  as  well  as  follow  up  data  on  disease  
recurrence  and  progression.  
  
BCPP  aimed  to  recruit  patients  within  the  West  Midlands  who  had  newly  
diagnosed  bladder  cancer  over  a  3-­‐‑year  period.    Specifically,  patients  over  the  
age  of  18  years  were  recruited  at  haematuria  clinics  based  on  cystoscopic  
findings  suggestive  of  bladder  cancer.    The  cohort  included  patients  with  any  
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stage  of  the  disease  providing  it  was  newly  diagnosed.    A  history  within  the  
last  decade  of  urethra,  bladder,  ureter  or  renal  pelvis  malignancy  excluded  
patients  from  the  cohort  as  did  a  diagnosis  of  HIV  infection  or  any  other  
condition  that  may  have  compromised  patient  safety.  
Data  collection  was  initiated  at  diagnosis  and  performed  by  research  nurses  
trained  to  interview  patients  prior  to  surgery  about  socio-­‐‑demographic  
information  such  as  age,  sex,  ethnicity,  education,  marital  status,  etc.  They  
also  asked  about  lifestyle  factors  (including  smoking  history,  exposure  to  
industrial  dyes,  etc.),  past  medical  history,  drug  history,  social  history  
including  dietary  intake  (total  fluid  intake,  alcohol,  caffeine,  sweeteners,  
vitamins),  family  history  and  social  support  networks.    The  European  
Organisation  for  Research  and  Treatment  for  Cancer  (EORTS)  questionnaire  
was  used  along  with  the  general  cancer  questionnaire  QLQ-­‐‑C30.  
In  addition,  patients  were  sent  a  self-­‐‑completion  questionnaire  after  
transurethral  resection  of  bladder  tumour  (TURBT)  and  prior  to  their  first  
follow-­‐‑up  at  around  3  months  from  initial  diagnosis.  
Biological  samples  including  blood,  urine,  fresh  and  formalin-­‐‑fixed  paraffin-­‐‑
embedded  tumour  samples  were  also  collected  at  diagnosis.  
Following  the  initial  TURBT  but  prior  to  the  first  follow-­‐‑  up  appointment  
patients  were  asked  to  complete  a  7  day  food  and  fluid  diary  and  give  toenail  
samples  to  measure  for  selenium  levels.    At  3  months  and  then  annually,  life  
style  factors,  quality  of  life  variables  and  patient  surveillance  preferences  
were  recorded  and  questionnaires  repeated.  
The  primary  endpoints  of  BCPP  were  disease  recurrence  and  progression.  
Recurrence  being  defined  as  new  occurrence  of  a  bladder  tumour  at  the  same  
or  different  site  as  the  initial  tumour.    Recurrences  identified  at  the  first  check  
cystoscopy  at  3  months  were  excluded  as  this  was  considered  to  be  
incomplete  resection  of  primary  tumour  at  the  initial  resection.  Progression  
was  defined  as  recurrence  with  an  increased  tumour  grade  compared  with  
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the  initial  tumour  ranging  from  grade  1  or  2  to  3,  or  an  increase  in  TNM  stage,  
or  new  occurrence  of  carcinoma  in  situ  (CIS),  or  new  multiple  tumours  
following  resection  of  a  solitary  lesion,  or  refractory  disease  requiring  a  
cystectomy.  
  
All  the  information  relating  to  the  BCPP  is  held  on  an  anonymised  database.  
For  the  purposes  of  this  study  a  subset  of  cases  were  selected  from  the  BCPP  
cohort  and  immunohistochemistry  was  performed.  Epidemiological  data  
from  the  database  was  extracted  and  a  new  smaller  database  was  established.  
This  database  was  then  updated  with  the  results  of  the  
immunohistochemistry  undertaken,  investigating  the  association  of  autotaxin  
with  bladder  cancer.    Statistical  analysis  was  performed  and  the  results  are  
discussed  in  subsequent  chapters.    More  information  is  available  in  the  
“Materials  and  Methods”  chapter.  
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1.2  Renal  Cancer  
  
Renal  cell  carcinoma  (RCC)  accounts  for  2-­‐‑3%  of  all  adult  malignancies  
(Campbell-­‐‑Walsh,  2012).    It  is  the  most  deadly  of  the  urological  malignancies.    
Historically,  there  has  been  a  30-­‐‑40%  mortality  rate  associated  with  RCC,  
compared  with  a  20%  mortality  rate  associated  with  bladder  and  prostate  
carcinomas  (Landis  et  al,  1999;  Pantuck  et  al,  2001b).      
  
1.2.1  Pathology  of  renal  cancer  
Renal  cell  carcinoma  (RCC)  is  the  most  common  of  the  renal  cancers  
accounting  for  90%  of  all  cases.  Although  RCC  tends  to  grow  as  a  single  
tumour  within  a  kidney,  there  may  be  more  than  one  tumour  within  any  
single  kidney.    The  three  commonest  types  of  RCC  are,  clear  cell,  papillary  
and  chromophobe  types.  Clear  cell  is  the  commonest  form  representing  80-­‐‑
90%  of  RCC.  Microscopically  clear  cell  type  is  composed  of  pale  or  clear  cells  
as  the  name  suggests.    Papillary  is  the  second  most  common  type  of  RCC  
accounting  for  approximately  10%  of  all  RCC.    Papillary  tumours  form  small  
finger-­‐‑like  projections  and  can  also  be  known  as  chromophilic  as  the  cells,  in  
the  presence  of  certain  dyes,  look  pink  under  the  microscope.    Chromophobe  
RCC  accounts  for  about  5%  of  all  RCC.    The  cells  of  this  type  are  also  clear  as  
in  clear  cell,  however  in  chromophobe  they  tend  to  be  larger  in  size.  
Rare  types  of  RCC  include  collecting  duct,  multilocular,  medullary,  mucinous  
and  spindle  cell.  
Other  types  of  renal  tumours  include  transitional  cell  carcinoma,  Wilm’s  
tumour  and  renal  sarcomas,  as  well  as  benign  tumours  such  as  oncocytomas  
and  angiomyolipomas.  
5-­‐‑10%  of  all  renal  cancers  are  transitional  cell  carcinoma  (TCC).    This  type  of  
tumour  begins  in  the  lining  of  the  renal  pelvis,  which  is  composed  of  
transitional  cells.    Wilm’s  tumour  almost  always  occurs  in  children.    Renal  
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sarcoma  is  rare  and  begins  in  the  blood  vessels  of  the  connective  tissue  of  the  
kidney.  This  type  accounts  for  <1%  of  all  kidney  cancers.  
Table  1.3  describes  the  major  subtypes  of  renal  cell  carcinoma.  
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of  RCC    






Most  cRCC  are  composed  
predominantly  of  cells  containing  
clear  cytoplasm,  although  
eosinophilic  cytoplasm  
predominates  in  some  cells.  The  
growth  pattern  may  be  solid,  
tubular,  and  cystic.    
Identified  by  the  
specific  deletion  
of  chromosome  3p  and  
mutation  of  the  VHL  
gene.  Other  changes  
are  duplication  of  the  
chromosome  band  
5q22,  deletion  of  
chromosome  6q,  8p,  9p,  




Most  pRCCs  have  small  cells  
with  scanty  cytoplasm,  but  also  
basophilic,  eosinophilic,  or  pale-­‐‑  
staining  characteristics.  A  papillary  
growth  pattern  predominates,  
although  there  may  be  tubular  
papillary  and  solid  architectures.  
Necrotic  areas  are  common.  
Papillary  RCC  can  be  divided  into  
two  different  subtypes:  type  1  with  
small  cells  and  pale  cytoplasm  and  
type  2  with  large  cells  and  
eosinophilic  cytoplasm,  the  latter  
having  a  worse  prognosis.    
The  most  consistent  
genetic  alterations  are  
trisomies  of  
chromosomes  3q,  7,  8,  
12,  16,  17,  and  loss  of  




The  cells  of  chRCC  may  have  pale  or  
eosinophilic  granular  cytoplasm.  
Growth  usually  occurs  in  solid  
sheets.    
The  genetic  
characteristic  are  a  
combination  of  loss  of  
chromosomes  1,  2,  6,  
10,  13,  and  17.    
  
1.2.2  Grade  and  Stage  of  renal  cancer  
Fuhrman  nuclear  grade  is  the  most  commonly  utilised  grading  system  used  
to  describe  renal  cancer.    The  most  aggressive  pattern  observed  defines  the  
Fuhrman  grade.    1  =  well-­‐‑differentiated,  2  =  moderately  differentiated,  3  and  4  
=  poorly  differentiated.  This  is  based  on  nuclear  size,  outline  and  nucleoli.    
The  grading  system  is  an  independent  prognostic  factor.    
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Leibovich  Score  (LS)  is  another  scoring  system  for  cRCC.  It  is  a  histological  
scoring  tool  that  takes  into  account  5  different  clinical  and  pathological  
parameters  and  has  been  used  in  cases  of  localized  cRCC  to  predict  likely  
progression  to  metastatic  cRCC  (Leibovich  et  al.  2003).  The  score  considers  
pathological  stage,  nodal  status,  tumour  size,  nuclear  grade  and  histological  
tumour  necrosis  (Ravand  et  al.  2008).  Using  these  parameters,  tumours  are  
assigned  a  score  ranging  from  zero  to  11  and  categorised  into  low-­‐‑  (0–2),  
intermediate-­‐‑  (3–5)  or  high-­‐‑risk  (≥6)  groups.  The  LS  can  accurately  assess  the  
risk  of  metastasis  in  patients  after  radical  nephrectomy  and  therefore  is  used  
to  guide  the  postoperative  intensity  of  follow-­‐‑up  and  possible  entry  into  
clinical  trials  for  patients  to  receive  adjuvant  therapy  (Vasdev  et  al.  2014).  
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Staging  is  based  on  the  2009  TNM  system  classification  system  and  can  be  
seen  in  table  1.4  below.  
  
Table  1.4  :  The  2009  TNM  staging  classification  system  for  Renal  Cell  
Carcinoma  (Sobin  et  al.  2009)  &  (Wittekind  et  al.  2012)  Taken  from  EAU  
Guidelines  2015.  
T-­‐‑  Primary  tumour  
TX        Primary  tumour  cannot  be  assessed  
T0          No  evidence  of  primary  tumour  
T1            Tumour  ≤7cm  in  greatest  dimension,  limited  to  the  kidney  
                      T1a  Tumour  ≤  4cm  in  greatest  dimension,  limited  to  the  kidney  
                      T1b  Tumour  >  4cm  but  ≤  7cm  in  greatest  dimension  
T2              Tumour  >  7cm  in  greatest  dimension,  limited  to  the  kidney  
                        T2a  Tumour  >  7cm  but  ≤  10cm  in  greatest  dimension  
                        T2b  Tumour  >  10cm  limited  to  the  kidney  
T3              Tumour  extends  into  major  veins  or  directly  invades  adrenal  gland  or    
                        perinephric  tissues  but  not  into  the  ipsilateral  adrenal  gland  and  not                          
beyond  Gerota’s  fascia  
    T3a    Tumour  grossly  extends  into  the  renal  vein  or  its  segmental  
(muscle  containing)  branches  or  tumour  invades  perirenal  and/or  renal  
sinus  (peripelvic0  fat  but  not  beyond  Gerota’s  fascia  
                        T3b  tumour  grossly  extends  into  the  vena  cava  below  the  diaphragm  
                        T3c  tumour  grossly  extends  into  vena  cava  above  the  diaphragm  or  
invades  the  wall  of  the  vena  cava  
T4              Tumour  invades  beyond  Gerota’s  fascia  (including  contiguous          
extension  into  the  ipsilateral  adrenal  gland)  
N-­‐‑  Regional  lymph  nodes  
NX  Regional  lymph  nodes  cannot  be  assessed    
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N0    No  regional  lymph  node  metastasis    
N1    Metastasis  in  a  single  regional  lymph  node    
N2    Metastasis  in  more  than  1  regional  lymph  node    
M-­‐‑  Distant  metastases  
M0    No  distant  metastasis    
M1    Distant  metastasis    
TNM  stage  grouping  
Stage  I                T1                                        N0        M0  
Stage  II              T2                                        N0        M0  
Stage  III            T3                                        N0        M0  
                                          T1,  T2,  T3            N1          M0  
  
  
1.2.3  Epidemiology  of  renal  cancer-­‐‑  Incidence  and  Mortality  
Approximately  12  new  cases  are  diagnosed  per  100,000  population  per  year.  
There  is  a  male-­‐‑to-­‐‑female  preponderance  of  3:2  (Landis  et  al,  1999;  Wallen  at  
al,  2007;  DeCastro  and  McKiernon,  2008;  Woldrich  et  al,  2008;  Carrizosa  and  
Godley,  2009).  
Typically,  RCC  presents  in  the  sixth  or  seventh  decade  of  life  (Pantuck  et  al,  
2001b;  Wallen  et  al,  2007).  Most  cases  of  RCC  are  believed  to  be  sporadic,  with  
only  2-­‐‑3%  thought  to  be  familial  (Lipworth  et  al,  2006).  
The  incidence  of  RCC  has  increased  in  recent  years  due  to  the  more  prevalent  
use  of  ultrasonography  and  CT  in  the  investigation  of  abdominal  symptoms  
and  therefore  the  incidental  finding  of  RCC  has  risen  greatly.  
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1.2.4  Renal  cancer  risk  factors  
There  are  three  known  risk  factors  for  RCC;  tobacco  exposure,  obesity  and  
hypertension.  The  greatest  risk  factor  is  tobacco  exposure  with  a  relative  risk  
ranging  from  1.4  to  2.5  compared  with  controls  (Wein  et  al.,  2012).    All  forms  
of  tobacco  appear  to  be  involved  and  risk  increases  with  increasing  dose  or  
pack-­‐‑years  (Kantor,  1977).  Relative  risk  is  directly  related  to  duration  of  
smoking  and  falls  gradually  after  cessation  (La  Vecchia  et  al,  1990).  
Obesity  is  another  important  risk  factor  for  RCC  with  a  relative  risk  of  1.07  for  
each  unit  of  rising  body  mass  index  (Chow  et  al.  2000).    There  is  an  increase  in  
both  obesity  and  RCC  in  Western  countries  with  around  40%  of  the  cases  of  
RCC  in  the  US  have  been  linked  to  obesity  (Calle  and  Kaaks,  2004).    Potential  
mechanisms  proposed  to  account  for  this  link  include  lipid  peroxidation  
resulting  in  DNA  adducts,  raised  expression  of  insulin-­‐‑like  growth  factor-­‐‑1,  
raised  oestrogen  levels  and  raised  arterionephroscellerosis  and  local  
inflammation  (Kasiske  et  al.,  1992,  Huang  et  al.,  1998,  Gago-­‐‑Dominguez  et  al.,  
2002)  
Hypertension  is  the  third  recognized  risk  factor  for  RCC.      There  have  been  
suggestions  that  it  is  the  treatment  for  hypertension  such  as  anti-­‐‑
hypertensives  and  diuretics  that  are  responsible  for  the  increased  risk  of  RCC.  
However  the  weight  of  evidence  now  suggests  that  it  is  the  underlying  
disorder  rather  than  the  treatment  (McLaughlin  et  al.  1995,  Yuan  et  al.,  1998,  
Lipworth  et  al.,  2006).    Renal  injury  caused  directly  by  hypertension  as  well  as  
inflammation  and  metabolic  and  functional  changes  in  the  renal  tubules  are  
thought  to  increase  the  vulnerability  to  carcinogens  (Lipworth  et  al,  2006).  
  
1.2.5  Existing  treatments  for  renal  cancer  
Treatment  of  localized  disease  involves  surveillance  of  small  renal  masses,  
surgery,  either  radical  or  partial  nephrectomy  with  or  without  adrenalectomy  
and  lymph  node  dissection,  or  percutaneous  approaches.    These  are  
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minimally  invasive  techniques  and  include  percutaneous  radiofrequency  
ablation  (RFA),  cryoablation  (CAB),  microwave  ablation,  laser  ablation  and  
high-­‐‑intensity  focused  ultrasound  ablation  (HIFU).  
Treatment  for  metastatic  disease  involves  surgery  usually  in  the  form  of  a  
debulking  cytoreductive  nephrectomy;  a  tumour  nephrectomy.    For  the  
majority  of  patients  this  is  a  palliative  procedure  and  other  treatments  will  
ultimately  be  required,  such  as  radiotherapy  especially  if  bone  metastases  are  
present.  
Systemic  treatment  for  metastatic  RCC  involves  a  combination  of  
chemotherapy,  interleukin-­‐‑2  and  angiogenesis  inhibitor  drugs  and  more  
recently  immune  checkpoint  inhibitors.  
  
1.2.6  Molecular  Biology  of  Renal  Cancer  
  
The  histological  subtypes  of  RCC  have  been  outlines  above.  The  molecular  
genetics  underlying  these  subtypes  has  allowed  the  development  of  
molecular  targeted  agents  that  have  extended  survival  especially  in  patients  
with  metastatic  RCC.  
An  example  of  this  is  von  Hippel-­‐‑Lindau  disease  which  is  a  familial  form  of  
clear  cell  RCC.  It  is  a  rare  autosomal  dominant  disease  affecting  1  in  36,000  
live  births.  There  are  3  major  manifestations  of  the  disease  and  these  are  clear  
cell  RCC,  haemangioblastoma  of  the  retina  and  cerebellum  and  
phaeochromocytoma.  It  is  characterized  by  inheritance  of  a  mutated  VHL  
tumour  suppressor  gene  on  the  short  arm  of  chromosome  3  (3p25-­‐‑26).      
The  main  function  of  the  VHL  gene  is  to  target  the  hypoxia-­‐‑inducible  factors  1  
and  2  (HIF-­‐‑1  and  HIF-­‐‑2)  for  ubiquitin-­‐‑mediated  degradation,  ensuring  levels  
of  HIFs  are  kept  low  under  normal  conditions.  Inactivation  or  mutation  of  the  
VHL  gene  therefore  results  in  inappropriate  HIF  1  and  2  up-­‐‑regulation  and  
accumulation  in  cells  under  normoxic  conditions.  This  subsequently  causes  
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up-­‐‑regulation  of  vascular  endothial  growth  factor  (VEGF),  which  is  the  
primary  growth  factor  in  RCC  (Wein  et  al.  2012).    
The  VHL  pathway  is  illustrated  in  figure  1.1  below.  
Knowledge  of  the  molecular  basis  of  VHL  has  enabled  the  development  of  
Sunitinib,  which  is  a  tyrosine  kinase  inhibitor.  Specifically  sunitinib  inhibits  
VEGF  and  platelet  derived  growth  factor  (PDGF).    Motzer  et  al.  2006  found  
that  in  106  patients  who  underwent  radical  nephrectomy  and  then  treatment  
with  Sunitinib  there  was  an  overall  response  rate  of  33%  with  a  14  month  
median  duration  of  response.  Median  survival  progression  free  survival  was  
8.8  months  and  overall  survival  was  23.9  months.  
  
Figure  1.1  The  VHL  and  HIF  Pathway  under  normal  conditions  and  in  RCC,  
showing  the  part  of  Sunitinib’s  place  in  the  pathway.  
(Taken  from  :  Marston  Linehan  W  &  Srinivasan  R  (2013).  Targeted  therapies:  
treating  advanced  kidney  cancer-­‐‑miles  to  go  before  we  sleep.  Nature  reviews  
Clinical  Oncology  10,  614-­‐‑615.  
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1.3  Biomarkers  
  
There  has  been  increasing  interest  in  recent  years  around  personalized  
medicine  and  management  of  diseases.  Biomarkers  have  become  an  
important  tool  in  this  process.  There  are  different  categories  of  markers  that  
play  a  role  in  different  stages  of  the  disease  process.  
  
Diagnostic  markers  are  parameters  that  can  aid  in  the  diagnosis  of  diseases.  For  
example  it  has  been  proposed  that  sputum  minichromosome  maintenance  
(MCM)  immunocytochemistry  could  be  used  in  the  diagnosis  of  lung  cancer  
(Ramnath  et  al.  2001,  Hashimoto  et  al.  2004).  
  
Prognostic  markers  refer  to  a  marker  that  provides  information  on  the  likely  
course  of  the  cancer  disease  in  the  untreated  individual.  For  example,  a  
prognostic  marker  could  identify  those  patients  with  cancers  most  likely  to  
recur  after  initial  surgical  treatment  for  example  and  therefore  those  who  
would  benefit  from  adjuvant  systemic  treatment.  
  
Predictive  biomarkers  refer  to  markers  that  can  be  used  to  select  the  therapy  
with  the  highest  likelihood  of  success  in  a  given  individual  patient.  They  help  
identify  subgroups  of  individuals  who  are  most  likely  to  respond  to  a  
particular  therapy.  Therefore  predictive  biomarkers  form  the  basis  for  
personalized  or  individualized  therapy.    For  example,  oestrogen  and  
progesterone  receptors  are  used  to  predict  whether  or  not  a  patient  will  
respond  to  endocrine  therapy  in  breast  cancer.  Her2  status  is  used  to  predict  if  
a  patient  will  respond  to  Herceptin  and  KRAS  mutation  is  used  to  predict  
whether  a  patient  will  demonstrate  resistance  to  EGFr  antibody  therapy.  
  
Autotaxin  has  the  potential  to  be  a  valuable  biomarker.  
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1.4  Autotaxin  
  
Autotaxin  (ATX),  encoded  by  the  ENNP2  gene,  is  a  member  of  the  ecto-­‐‑
nucleotide  pyrophosphatase/phosphodiesterase  enzyme  family  (NNP).  It  was  
first  reported  in  1992  when  it  was  identified  as  a  tumour  cell  motility  factor  in  
a  melanoma  cell  line  (Stracke  et  al.  1992).    It  is  a  125-­‐‑kilodalton  glycoprotein  
and  is  present  in  biological  fluids  such  as  cerebrospinal  fluid  (CSF),  malignant  
ascites  and  blood  (Fotopoulou  et  al.  2010).    It  is  encoded  by  a  single  gene  on  
human  chromosome  8  and  has  3  different  isoforms;  α,  β,  and  γ  (Tania  et  al.  
2010).  It  is  synthesized  as  a  pro-­‐‑enzyme  and    secreted  into  the  extracellular  
space  (Jansen  et  al.  2005).  Autotaxin  is  then  thought  to  communicate  and  
influence  target  cells  via  integrins  (Houben  et  al.  2011).  It  is  found  in  higher  
concentrations  in  the  blood  of  women  (0.625-­‐‑1.323mg/L)  than  in  men  (0.438-­‐‑
0.914mg/L)  (Nakamura  et  al.  2008)  and  has  been  shown  to  play  a  role  in  
several  diseases  and  conditions  including  obesity  (Ferry  et  al.  2003),  
rheumatoid  arthritis  (Bourgoin  et  al.  2010),  chronic  pain  (Inoue  et  al.  2008a,  
Inoue  et  al.  2008b),  and  cancer  (Okudaira  et  al.  2010).  Recent  studies  have  
suggested  that  ATX  expression  in  cancer  cells  has  a  direct  role  in  promoting  
bone  metastases  and  that  by  silencing  ATX  expression  in  these  cells  bone  
metastases  are  reduced  without  reduction  in  tumour  volume  (David  et  al.  
2010).    
  
Autotaxin  is  active  in  the  lysophosphatidic  acid  (LPA)  pathway  (figure  1.2)  
and  is  responsible  for  the  conversion  of  lysophosphatidyl-­‐‑choline  (LPC)  to  
LPA.      
LPA  is  a  phospholipid  derivative  that  acts  as  a  signaling  molecule.    It  was  first  
identified  in  ovarian  cancer  by  Sedlakova  et  al.  in  2006.  They  reported  plasma  
LPA  levels  to  be  higher  in  patients  with  ovarian  cancer  compared  with  
controls  with  no  ovarian  pathology  and  patients  with  benign  ovarian  disease  
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(Sedlakova  et  al  2008).  They  also  found  that  plasma  LPA  levels  were  
associated  with  stage  and  histological  type  of  ovarian  cancer  and  concluded  
that  LPA  could  be  used  as  a  useful  marker  for  ovarian  cancer  especially  the  
early  stages  of  the  disease.    
LPA  elicits  a  variety  of  responses  by  binding  to  one  or  more  of  6  specific  G  
protein-­‐‑coupled  receptors,  (encoded  by  LPAR  genes  1-­‐‑6),  which  in  turn  initiate  
subsequent  cell  signaling  pathways  resulting  in  cell  proliferation,  survival,  
motility,  invasion,  and  angiogenesis.    As  such,  aberrant  LPA  signaling  has  
been  linked  to  various  types  of  cancer.  
The  role  of  each  of  the  LPA  receptors  is  not  clear,  however  loss  of  LPA6  
function  has  been  implicated  in  the  development  of  bladder  cancer,  
suggesting  that  LPA6  may  be  a  tumour  suppressor  (Mills  et  al.  2003,  Lee  et  al.  
2007,  Houben  et  al.  2011).      
Similarly,  LPA1  mRNA  expression  was  found  to  be  significantly  higher  in  
muscle  invasive  bladder  cancer  specimens  than  in  non-­‐‑muscle  invasive  
specimens  (Kataoka  et  al.  2014)  and  strong  LPA1  expression  was  reported  on  
the  cell  membranes  in  muscle  invasive  specimens.  
  
Renal  cancer  is  a  highly  vascular  tumour  thought  to  be  dependent  on  aberrant  
angiogenesis  (Su  et  al.  2013).      Su  et  al.  showed  that  autotaxin  was  exclusively  
expressed  in  RCC  tumour  vessels  but  neither  in  tumour  cells  nor  in  normal  
renal  capillaries.  They  also  found  that  autotaxin,  produced  by  RCC  
endothelium,  acted  through  LPA  signaling  to  promote  tumourigenesis  so  
they  proposed  a  role  for  the  autotaxin-­‐‑LPA  signaling  pathway  in  renal  cancer  
progression.    
VEGF  signalling  pathway  has  also  been  associated  with  renal  angiogenesis  
and  is  the  target  for  Sunitinib,  which  is  the  standard  treatment  for  advanced  
RCC.    Su  et  al.  (2013)  looked  at  the  development  of  acquired  resistance  
against  Sunitinib  in  RCC  and  the  role  of  autotaxin  in  it.  They  found  that  
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autotaxin  expression  was  increased  in  the  tumour  vasculature  of  RCC  but  
decreased  with  the  treatment  of  Sunitinib.  They  proposed  a  role  for  the  
autotaxin-­‐‑LPA  signaling  pathway  in  the  acquired  resistance  of  RCC  to  
Sunitinib  through  targeting  tumour  cell  and  vascular  interactions.  
  
Therefore,  it  is  clear  that  autotaxin  is  an  essential  component  in  the  LPA  
pathway  and  that  a  major  function  of  that  pathway  is  tumour  cell  survival  
and  invasion,  and  angiogenesis.  The  potential  role  of  autotaxin  as  an  
attractive  therapeutic  target  is  obvious.  
In  this  thesis  the  relation  between  autotaxin  expression  and  the  clinico-­‐‑
pathological  variables  in  two  cohorts,  bladder  and  renal  cancer,  was  
investigated.  
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Figure  1.2  The  LPA  Pathway  




     
	   29	   	  
Materials  and  Methods  
  
This  chapter  describes  the  basic  laboratory  techniques  used.    Any  




All  tissue  samples  used  in  these  studies  were  from  archival,  formalin  fixed  
paraffin  embedded  tissue  blocks,  Department  of  Pathology,  University  
Hospital  Birmingham.  Tissue  sections  were  cut  at  4µμm  on  a  rotatory  
microtome,  placed  onto  charged  slides  (PFM,  UK)  and  heated  in  a  600C  
incubator  for  1  hour  prior  to  use.  
  
2.2  Immunohistochemistry  
Two  related  immunohistochemistry  approaches  were  used.  Both  gave  similar  
results.  
  
2.2.1  Citrate  Buffer  Retrieval  Method  
Paraffin  embedded  sections  of  bladder  or  renal  cancer  tissue  were  baked  in  
the  oven  at  60  degrees  for  1  hour.    The  citrate  buffer  was  made  using  1.26g  
sodium  citrate,  0.25g  citric  acid,  and  1L  H2O.  The  pH  was  adjusted  to  pH6  
with  concentration  of  NaOH.    The  water  bath  was  heated  to  a  temperature  of  
96  degrees  and  the  container  of  citrate  buffer  was  placed  in  the  water  bath.    
The  slides  were  immersed  in  Histoclear  for  10  minutes  then  IMS  for  a  further  
10  minutes.    They  were  then  rinsed  with  water  for  5-­‐‑10  minutes.    Slides  were  
immersed  in  hydrogen  peroxide  0.3%  (1:100  dilution  of  30%  H2O2  stock  in  
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dH2O)  for  10  minutes  and  then  rinsed  with  water  for  a  further  5-­‐‑10  minutes.    
The  slides  were  then  placed  in  the  hot  citrate  buffer  for  20  minutes.  
Following  antigen  retrieval  slides  were  taken  out  and  allowed  to  cool  for  30  
minutes  -­‐‑1  hour  and  then  rinsed  in  water  for  10  minutes.  
Using   a  marker   pen   a   circle   was   carefully   drawn   around   the   tissue.   Slides  
were  placed  in  Tris  buffered  saline  pH  7.6  (TBS)  for  5  minutes  then  the  section  
of   tissue  was   covered  with   horse   serum   2.5%   for   30-­‐‑40  minutes.   The   liquid  
was  removed  from  the  slides  and  then  the  tissue  was  covered  with  primary,  
rat  monoclonal  antibody  2B4  (1:200)  against  autotaxin  (1µμL  of  abx:  200µμL  of  
PBS)   on   each   slide   (200µμl  per   slide)   and  placed   in   the   fridge  overnight   at   4  
degrees.    Following  this  the  slides  were  rinsed  in  TBST  for  20-­‐‑30  minutes  and  
then   the   secondary   antibody   (rabbit   anti-­‐‑rat   (Vector,   UK)   at   1/200   dilution)  
was  applied  for  10  minutes.  The  slides  were  once  again  rinsed  with  TBS  for  10  
minutes  and  then  the  tertiary  reagent  was  applied  for  30  minutes,  then  rinsed  
with  TBST  for  a  further  30  minutes.  
The   immunostaining   procedure   was   then   visualized   with   3,3-­‐‑
diaminobenzidine   (DAB)   (30µμl   in   1   ml   dilutent,   putting   150-­‐‑200µμl   on   each  
slide   for   1   minute)   according   to   the   manufacturer’s   instruction.   They   were  
then  rinsed  with  water  for  5  mins,  haemotoxylin  for  1.5  mins,  cold  water  for  2  
mins,  hot  water  for  2  mins,  cold  water  again  for  2  min,  IMS  for  10  mins,  then  
histoclear   for   10   mins.      Following   this   the   tissue   was   mounted   using   DPX  
mountant.  
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2.2.2  The  ALTER  Method  
The   second   retrieval   method   involved   de-­‐‑paraffinising   the   sections   and  
rehydrated  to  water  as  previously  described  (2.2.1).  After  a  low  temperature  
retrieval   technique,   ALTER   (Reynolds   et   al   2002)   immuno-­‐‑staining   was  
performed   on   a   Dako   Autostainer.   In   brief   this   comprised   of   a   10-­‐‑minute  
endogenous   peroxidise   block   (Dako,   UK)   followed   by   a   10-­‐‑minute   protein  
block   in   2%   casein   (Vector   Labs,   UK).   Sections   were   then   incubated   in  
optimally   diluted   autotaxin   antibody   for   one   hour,   rabbit   anti-­‐‑rat   (Vector  
Labs,   UK)   at   1/200   dilution   for   10   minutes,   Vector   ImmPRESS   rabbit  
secondary   for   30   minutes   and   visualised   in   NovaRED   chromagen   (Vector  
Labs,  UK)   for   5  minutes.  All   buffer  washes  were   performed  with   EnVision  
FLEX   wash   buffer   (Dako,   UK).   Sections   were   counterstained   with   Meyers  
haematoxylin,  dehydrated  and  mounted  with  a  glass  coverslip  in  DPX.      
  
     
	   32	   	  
2.3  Scoring  of  Autotaxin  Expression  
After  staining  was  completed,  the  cases  were  interpreted  by  two  independent  
observers,  a  consultant  histopathology  and  myself.  They  were  scored  
according  to  whether  autotaxin  expression  was  ‘strong’,  ‘weak’,  or  ‘negative’.      
Examples  of  each  category  are  shown  in  Figure  2.2.1a-­‐‑d  and  2.2.2a-­‐‑c  in  the  
bladder  and  renal  chapters  respectively.  None  of  the  renal  cancer  tumours  
were  positive  for  autotaxin,  but  the  tumour  endothelium  was,  so  expression  
in  figures  2.2.2a-­‐‑2.2.2c  refers  to  vessels  only.  
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2.4  Databases  
  
2.4.1  Bladder  Database  
The  bladder  database,  as  seen  in  Figure  2.3.1  below,  was  initially  created  as  
part  of  the  West  Midlands  bladder  cancer  prognosis  programme  (BCPP).    It  
includes  extensive  epidemiological  information  on  over  1000  patients  with  
bladder  cancer  within  the  West  Midlands.  In  this  study  a  smaller  subset  of  the  
original  database  was  used  to  populate  a  new  database.  
Among  some  of  the  variables  included  in  the  database  were  gender,  date  of  
birth,  age  at  recruitment,  disease  status  at  death,  cause  of  death,  grade  and  
stage  of  disease,  marital  status,  ethnicity,  smoking  status,  and  other  medical  
comorbidities  such  as  depression,  myocardial  infarction,  arrhythmias,  
pulmonary  emboli,  stroke  and  diabetes  and  date  of  recurrence  of  disease.  
Paraffin  embedded  tissue  blocks  were  available  for  all  patients  in  the  
database.  Blocks  were  retrieved  and  fresh  sections  cut  before  performing  
immunohistochemistry.  
The  database  was  then  updated  and  new  information  regarding  autotaxin  
expression  in  this  cohort  was  added.  
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Figure  2.3.1  –  Screenshot  of  the  bladder  database     
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2.4.2  Renal  Database  
The  renal  database  (seen  in  Figure  2.3.2  below)  was  initially  created  to  
establish  epidemiological  information  of  a  cohort  of  metastatic  renal  cell  
carcinoma  patients  who  were  being  treated  with  Sunitinib.    It  included  59  
patients,  14  females  and  45  males  with  a  median  age  of  60  years.  Renal  
biopsies  were  taken  from  each  patient  prior  to  commencing  treatment  with  
Sunitinib.  Paraffin  embedded  tissue  blocks  were  available  for  all  patients.  
Blocks  were  retrieved  and  fresh  sections  cut  in  preparation  for  
immunohistochemistry.  
The  database  was  updated  as  part  of  the  current  piece  of  work  and  new  
information  was  gathered.  This  involved  retrieving  information  from  hospital  
notes,  letters  and  on-­‐‑line  databases.  
Among  some  of  the  variables  included  in  the  database  were  gender,  age,  
grade  and  stage  of  disease,  date  of  starting  Sunitinib  treatment,  vascular  
invasion  of  the  tumour,  fat  necrosis,  sarcomatoid  component,  heng  score,  date  
of  last  follow-­‐‑up,  VEGF-­‐‑R  status,  SPHK1  status,  and  CA-­‐‑9  status.  
All  patients  had  their  histology  reviewed  by  a  consultant  pathologist,  date  of  
last  follow-­‐‑up  was  updated  as  well  as  date  of  death,  and  autotaxin  expression  
established  by  immunohistochemistry  was  added.  
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Figure  2.3.2  –  Screenshot  of  the  renal  database  
  
2.5  Statistical  Analysis  
All  quantifiable  data  were  subjected  to  statistical  analysis  in  the  IBM  SPSS  
Statistics  (version  21).  The  advice  of  an  experienced  statistician  was  sought  to  
guide  the  appropriate  use  of  tests.  P  values  were  taken  to  indicate  a  
significant  difference  between  the  data  sets  when  the  P  was  below  0.05.  
Pearson’s  Chi-­‐‑  Square  test  is  used  to  decipher  whether  or  not  a  significant  
relationship  existed  between  two  categorical  variables.  Essentially  it  measures  
how  well  the  observed  distribution  of  data  fits  with  the  distribution  expected  
if  the  variables  are  independent.    It  is  suitable  for  unpaired  data  and  large  
samples.  
Linear-­‐‑by  Linear  Association  test  considers  the  trend  of  the  data  and  indicates  
the  strongest  association  between  two  variables.  It  represents  any  relationship  
between  two  variables  that  depict  a  straight  line  when  plotted  next  to  each  
other  in  a  graph.  It  is  used  for  ordinal  categorical  data  sets.  
When  numbers  were  small  Fischer’s  Exact  Test  was  used  rather  than  Pearson’s  
Chi-­‐‑Square.  It  assesses  whether  or  not  two  classifications  are  associated.  It  is  
used  with  categorical  data.  
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Kappa  statistic  and  coefficient  is  a  statistic  that  measures  inter-­‐‑rater  agreement  
for  qualitative,  categorical  items.  It  was  used  to  assess  the  association  between  
autotaxin  expression  in  vessels  compared  with  expression  in  tumour.  
When  considering  the  relationship  between  autotaxin  expression  and  survival  
log  rank  tests  were  used.    Log  rank  tests  compare  the  survival  times  between  
two  or  more  groups  (non-­‐‑parametric),  such  as  strong  and  weak  autotaxin  
expression.  The  null  hypothesis  for  a  log  rank  test  is  that  the  groups  have  the  
same  survival.  
Kaplan-­‐‑Meiers  estimate  is  used  to  measure  the  fraction  of  subjects  living  for  a  
certain  time  after  a  treatment/event.  The  starting  point  in  this  piece  of  work  
was  histology  date  and  the  terminating  event  was  time  to  death.  The  resulting  
Kaplan-­‐‑Meier  product  was  plotted  creating  a  survival  curve.  
Multivariate  survival  analysis  was  also  undertaken.  This  technique  is  used  to  
analyze  data  that  may  arise  from  more  than  one  variable,  for  example,  
gender,  disease  grade  and  stage,  lymph  node  status  and  number  of  metastatic  
sites.  Multivariable  analysis  was  used  with  the  renal  cohort  but  not  with  the  
bladder  cohort  as  the  number  of  positive  stainers  was  too  small.  Univariate  
analysis  on  the  bladder  cohort  did  not  show  any  significant  effects  for  
autotaxin  and  therefore  multivariate  analysis  was  considered  unnecessary.  
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Expression  of  Autotaxin  in  Relation  to  
Clinico-­‐‑pathological  Finding  in  a  
Cohort  of  Bladder  Cancer  Patients  
     
3.1  Introduction    
In  the  U.K.  bladder  cancer  is  the  fourth  most  common  malignancy  in  males  
and  the  12th  most  common  in  females.  It  affects  >10,000  individuals  each  year  
(www.statistics.gov.uk).    It  is  the  most  common  tumour  occurring  in  the  
urinary  tract  and  accounts  for  one  in  every  28  new  cases  of  cancer  every  year  
(Zeegers  et  al.  2009).    Bladder  cancer  is  responsible  for  >  5,000  deaths  each  
year  in  the  UK  (ONS).  Both  incidence  and  mortality  rates  increase  with  age  
and  given  the  ageing  population  bladder  cancer  will  remain  an  important  
health  problem.      
  
The  majority  of  bladder  cancers  (70%)  are  either  confined  to  the  lamina  
propria  or  superficial  to  this  i.e.,  non-­‐‑muscle  invasive.    These  patients  
undergo  extensive  life-­‐‑long  follow-­‐‑up  with  cystoscopy.  While  many  patients  
find  on  going  surveillance  reassuring  others  find  it  stressful.    Schoever  et  al.  
(1987)  reported  adverse  psychological  impact  caused  by  long-­‐‑term  
cystoscopic  follow-­‐‑up  and  intravesical  treatment.  
In  terms  of  healthcare  expenditure,  bladder  cancer  is  the  5th  most  expensive  
cancer  to  treat  in  the  U.S.  (Botteman  et  al.  2003).  Furthermore,  among  all  
cancers  treated  with  in  the  Medicare  system  it  has  been  found  to  have  the  
highest  cost  per  patient  from  diagnosis  to  death  (Riley  et  al.  1995).    Cost  of  
patient  management  for  bladder  cancer  in  the  UK  has  previously  been  found  
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to  be  more  expensive  than  other  cancers  for  example,  prostrate  cancer  (Sangar  
et  al.  2005).    
  
However,  it  is  not  only  the  cost  of  treating  bladder  cancer  that  is  the  problem,  
some  of  the  current  treatments  risk  significant  side  effects.  BCG  or  Bacillus  
Calmette-­‐‑Guerin  for  example,  was  first  used  as  a  treatment  for  bladder  cancer  
by  Morales  in  1976.  Its  role  is  in  the  treatment  of  intermediate  and  high-­‐‑risk  
non-­‐‑muscle  invasive  bladder  cancer.  It  is  live  attenuated  Mycobacterium  
bovis.  Although  not  well  understood,  the  mechanisms  of  action  are  thought  to  
include  the  attachment  of  BCG  to  the  urothelium  via  the  fibronectin  receptor  
which  is  then  internalized  within  the  bladder  cancer  cell.    It  is  also  thought  to  
promote  the  secretion  of  cytokines  and  chemokines,  and  the  presentation  of  
BCG  and/or  cancer  cell  antigens  to  cells  of  the  immune  system  (Redelman-­‐‑
Sidi  et  al.  2014).  
Sylvester  et  al.  (2002)  meta-­‐‑analysis  of  24  randomised  trials  involving  4863  
patients  with  non-­‐‑muscle  invasive  bladder  cancer  found  that  an  induction  
followed  by  maintenance  of  BCG  following  initial  resection  of  bladder  
tumour  resulted  in  a  relative  risk  reduction  of  disease  progression  of  27%.  
Common  side  effects  experienced  when  having  BCG  treatment  for  bladder  
cancer  include  urinary  frequency,  dysuria,  malaise  and  mild  fever  for  up  to  24  
hours  after  treatment.  Less  common  but  more  serious  side  effects  include  
arthralgia,  rash,  headache,  and  high  fever  for  at  least  48  hours.  These  
symptoms  suggest  BCG  sepsis  and  require  urgent  medical  attention  and  anti-­‐‑
tuberculosis  therapy  as  well  as  steroids.  
  
A  second  treatment  currently  used  for  non-­‐‑muscle  invasive  bladder  cancer  is  
mitomycin  C  (MMC).  It  is  an  anti-­‐‑tumour  antibiotic  and  its  mechanism  of  
action  involves  cross-­‐‑linking  complementary  DNA  strands  and  alkylates  in  
bladder  tumour  cells.    
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Sylvester  et  al.  (2004)  found  that  a  single  post-­‐‑operative  dose  of  intravesical  
MMC  within  the  first  24  hours  following  bladder  tumour  resection  resulted  in  
a  39%  decrease  in  the  relative  risk  of  recurrence  with  adjuvant  treatment.  
Side  effects  of  MMC  include  irritation  to  the  skin  if  it  comes  in  contact,  
urinary  tract  infections  with  symptoms  of  frequency,  dysuria  and  systemic  
upset,  and  if  it  is  inadvertently  given  in  the  presence  of  a  bladder  perforation  
the  MMC  can  then  be  absorbed  into  the  blood  stream  and  results  in  
haematological  abnormalities  as  well  as  pain  and  discomfort  with  in  the  
peritoneal  cavity.  
Therefore,  current  treatment  of  bladder  cancer  not  only  poses  a  financial  
burden  but  also  can  lead  to  serious  side  effects  to  the  patient.  
  
One  potential  therapeutic  target  in  bladder  cancer  is  autotaxin.  Autotaxin  is  
an  enzyme  that  converts  LPC  to  LPA.    Little  is  known  about  the  expression  of  
autotaxin  and  if  it  is  involved  in  the  pathogenesis  of  bladder  cancer.  Lee  et  al.  
(2007)  found  a  link  between  familial  bladder  cancer  and  the  LPA6  receptor  but  
literature  search  found  no  other  report  of  either  autotaxin  expression  or  LPAR  
expression  in  bladder  cancer.  
  
Were  autotaxin  shown  to  be  expressed  then  autotaxin  inhibitors  might  be  
considered  in  the  treatment  of  patients  with  bladder  cancer.  
  
The  work  set  out  in  this  chapter  aimed  to  describe  autotaxin  expression  in  
bladder  cancer  and  its  relationship  to  clinico-­‐‑pathological  observations.  
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3.2  Materials  and  Methods  
New  sections  were  made  from  paraffin  embedded  blocks  available  from  the  
BCPP  cohort.  An  antibody  targeting  autotaxin  was  validated  using  tonsil  
samples  and  was  then  used  to  stain  the  bladder  sections  for  autotaxin  
expression.  Immunohistochemistry  was  performed  using  the  methods  set  out  
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3.3  Results  
I  first  performed  a  pilot  study  comprising  124  cases  of  bladder  cancer  to  
establish  the  prevalence  of  autotaxin  expression  and  to  determine  if  analysis  
of  a  larger  cohort  was  likely  to  produce  meaningful  results.  
  
  
3.3.1.1  Autotaxin  Expression  and  Association  with  Stage  of  Bladder  Cancer  
32/124  cases  expressed  autotaxin  within  tumour  cells.  pT2  tumours  were  
more  likely  to  show  strong  staining  (27%  versus  7%)  however  the  significance  
tests  (both  for  association  and  for  linear  trend)  showed  a  trend  to  statistical  
significance  with  p=0.060  and  p=0.069  respectively.  
  










pTa   Count   53   11   5   69  
   %  within  stage   76.8%   15.9%   7.2%   100%  
pT1   Count   24   3   2   29  
   %  within  stage   82.8%   10.3%   6.9%   100%  
pT2   Count   15   4   7   26  
   %  within  stage   57.7%   15.4%   26.9%   100%  
Total   Count   92   18   14   124  
   %  within  stage   74.2%   14.5%   11.3%   100%  
Table  3.3.A  –  Autotaxin  Staining  vs.  Tumour  Stage  
  






8.886   4   0.064   0.060  
Linear-­‐‑by-­‐‑Linear  
Association  
3.312   1   0.069   0.069  
N  of  Valid  Cases   124           
Table  3.3.B  –  Statistical  Analysis  of  Autotaxin  Staining  vs.  Tumour  Stage    
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Next,  the  impact  of  autotaxin  expression  on  presence  or  absence  of  tumour  
invasion  into  muscle  was  examined.    Muscle  invasion  is  an  important  
prognostic  factor  with  muscle  invasion  indicating  a  poorer  prognosis.    
  
77/92  (78.6%)  patients  with  non-­‐‑muscle  invasive  disease  pTa/pT1  showed  no  
autotaxin  expression  compared  with  15/26  (57.7%)  of  patients  with  muscle  
invasive  tumours  pT2.    7/98  (7.1%)  of  non-­‐‑muscle  invasive  pTa/pT1  showed  
strong  autotaxin  expression  compared  with  7/26  (26.9%)  of  muscle  invasive  
pT2.    When  pT2  (invasive)  were  compared  with  pTa  and  pT1  combined,  both  
an  association  and  a  trend  were  significant  (p=0.015  and  p=0.009).      
This  suggests  that  autotaxin  expression  is  associated  with  muscle  invasion  
and  as  such  autotaxin  could  be  a  marker  of  a  poorer  prognosis  in  bladder  
cancer.  
  













Count   77   14   7   98  
   %  within  
NMI  
78.6%   14.3%   7.1%   100%  
Muscle  
Invasive  (pT2)  
Count   15   4   7   26  
   %  within  
MI  
57.7%   15.4%   26.9%   100%  
Total   Count   92   18   14   124  
   %     74.2%   14.5%   11.3%   100%  
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8.345   2   0.015   0.015  
Linear-­‐‑by-­‐‑Linear  
Association  
7.339   1   0.007   0.009  
N  of  Valid  Cases   124           
Table  3.3.D  –  Statistical  Analysis  of  Autotaxin  Staining  vs.  Presence  or  
Absence  of  Muscle  Invasion    
  
Furthermore,  when  comparing  the  relationship  between  muscle  invasion  and  
autotaxin  expression  following  re-­‐‑grouping  in  to  ‘none’  staining  versus  
‘weak/strong’  staining,  77/97  (78.6%)  of  non-­‐‑muscle  invasive  group  showed  
no  autotaxin  expression  compared  with  15/26  (57.7%)  of  the  muscle  invasive  
group.    21/98  (21.4%)  of  the  non-­‐‑muscle  invasive  group  showed  weak/strong  
autotaxin  expression  compared  with  11/26  (42.4%)  of  the  muscle  invasive  
group.  The  association  between  muscle  invasiveness  and  the  weak/strong  
staining  group  was  significant  (p=0.031).    
  








Count   77   21   98  
   %  within  non-­‐‑  
muscle  invasive  
78.6%   21.4%   100%  
Muscle  
Invasive  
Count   15   11   26  
   %  within  muscle  
invasive  
57.7%   42.4%   100%  
Total   Count   92   32   124  
   %     74.2%   25.8%   100%  
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   Value   df   Asymp.  Sign.  (2-­‐‑sided)  
Pearson  Chi-­‐‑Square   4.679   1   0.031  
N  of  Valid  Cases   124        
Tables  3.3.F  –  Statistical  Analysis  of  Autotaxin  Staining  vs.  Dichotomized  
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Further  re-­‐‑grouping  in  to  ‘none/weak’  and  ‘strong’  groups  then  showed  that  
91/98  (92.9%)  of  non-­‐‑muscle  invasive  cohort  showed  no/weak  expression  
compared  with  19/26  (73.1%)  of  muscle  invasive.  7/93  (7.1%)  of  non-­‐‑muscle  
invasive  cohort  showed  strong  expression  compared  with  7/26  (26.9)  of  
muscle  invasive.    This  association  was  found  to  be  significant  (p=0.01).    
This  result  once  again  supports  the  contention  that  autotaxin  could  be  a  
marker  of  muscle  invasiveness  in  bladder  cancer  and  therefore  of  poorer  
prognosis.  
  







Count   91   7   98  
   %  within  non  
-­‐‑muscle  
invasive  
92.9%   7.1%   100%  
Muscle  
Invasive  
Count   19   7   26  
   %  within  
muscle  
invasive  
73.1%   26.9%   100%  
Total   Count   110   14   124  
   %     88.7%   11.3%   100%  













         0.010   0.010  
N  of  Valid  
Cases  
124              
Table  3.3.H  –  Statistical  Analysis  of  Autotaxin  Staining  vs.  Dichotomized  
Staining  (None/Weak  vs.  Strong)    
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3.3.1.2  Autotaxin  Tumour  Expression  versus  Grade  of  Tumour  
Tumour  grade,  based  on  the  1973  WHO  classification  discussed  above,  
describes  how  abnormal  the  tumour  cells  are  compared  with  normal  cells  
when  viewed  under  the  microscope.  It  is  an  indicator  of  how  the  tumour  will  
behave,  how  quickly  it  will  grow  and  spread.    If  the  tumour  cells  
morphologically  resemble  normal  cells  then  the  tumour  is  called  ‘well-­‐‑
differentiated’.  If  the  tumour  cells  are  very  different  to  normal  cells,  the  
tumour  is  called  ‘poorly  differentiated’.    Based  on  this  a  numerical  grade  is  
given  to  the  cancer.  
  
Tumour  grade  was  compared  with  autotaxin  expression.  Although  the  
percentage  of  cases  strongly  staining  increased  with  grade  (7%,  11%,  14%),  
this  linear  association  was  not  significant  (p=0.532).  
  










1   Count   23   6   2   31  
   %  with  
in  grade  
74.2%   19.4%   6.5%   100%  
2   Count   22   3   3   28  
   %  with  
in  grade  
78.6%   10.7%   10.7%   100%  
3   Count   48   9   9   66  
   %  with  
in  grade  
72.7%   13.6%   13.6%   100%  
Total   Count   93   18   14   125  
   %     74.4%   14.4%   11.2%   100%  





	   48	   	  
  







0.423   1   0.515   0.532  
N  of  Valid  
Cases  
124           
Table  3.3.J-­‐‑  Statistical  Analysis  of  Autotaxin  Tumour  Staining  vs.  Grade  of  
Tumour  Significance  Values  
  
3.3.1.3  Tumour  Grade  versus  Autotaxin  Expression  (Dichotomized,  
None/Weak  vs.  Strong)  
  
Tumour  grade  was  considered  in  relation  to  autotaxin  expression  when  
groups  were  separated  into  ‘none/weak’  and  ‘strong’  expression.  
29/31  (93.5%)  of  G1  cases  showed  none/weak  expression  compared  with  25/28  
(89.3)  of  G2  and  57/66  (86.4%)  of  G3.  
2/31  (6.5%)  of  G1  cases  showed  strong  expression  compared  with  3/28  (10.7%)  
of  G2  and  9/66  (13.6%)  of  G3.  
No  significant  association  or  trend  was  observed  (p=0.576,  p=0.320  
respectively).  





1   Count   29   2   31  
   %  with  in  
grade  
93.5%   6.5%   100%  
2   Count   25   3   28  
   %  with  in  
grade  
89.3%   10.7%   100%  
3   Count   57   9   66  
   %  with  in  
grade  
86.4%   13.6%   100%  
Total   Count   111   14   125  
   %     88.8%   12.2%   100%  
Table  3.3.K-­‐‑  Grade  vs.  Autotaxin  Staining  (Dichotomized,  None/Weak  vs.  
Strong)  
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1.085   1   0.298   0.320  
N  of  Valid  
Cases  
124           
Table  3.3.L-­‐‑  Statistical  Analysis  of  Grade  vs.  Autotaxin  Staining  
(Dichotomized,  None/Weak  vs.  Strong)  Significance  Values  
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3.3.2  The  Expanded  Cohort  
  
Having  demonstrated  an  association  between  autotaxin  expression  and  
muscle  invasiveness  in  the  pilot  cohort,  an  extended  cohort  was  assessed.  The  
pilot  124  cases  were  supplemented  with  a  further  241  to  achieve  a  cohort  of  
365  cases.  50  cases  were  excluded  for  technical  reasons  including  high  
background  and  poor  section  quality.    Because  I  had  also  observed  variable  
staining  of  vessels  in  the  initial  cohort,  vessel  staining  was  scored  in  all  cases.  
Autotaxin  staining  was  available  for  316  (vessels)  and  315  (tumours).  
There  were  no  CIS  or  T3-­‐‑4  included  in  the  cohort  and  therefore  analysis  only  
included  Ta-­‐‑T2.  
  
In  the  pilot  cohort  of  124  cases  autotaxin  staining  was  observed  in  79.4%  
(vessels)  and  25.6%  (tumour)  of  the  study  subjects.    
When  the  cohort  was  expanded  to  365  cases  the  prevalence  of  the  positive  
staining  fell  to  71.2%  (vessels)  and  12.7%  (tumour).    
  
  
   Autotaxin  -­‐‑  Vessels   Autotaxin  -­‐‑Tumour  
None   28.8%  (91)   87.3%  (275)  
Weak  Staining  
  
34.8%  (110)   7.3%  (23)  
Strong  Staining   36.4%  (115)   5.4%  (17)  
Positive  for  Staining   71.2%  (225)   12.7%  (40)  
Table  3.3.M  –  Summary  of  Staining  Results  for  the  Expanded  Cohort  
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3.3.2.1  Autotaxin  Expression  in  Tumour  versus  Stage  
  
An  association  between  autotaxin  expression  in  tumour  and  stage  was  then  
evaluated.  128/146  (87.7%)  of  pTa  showed  no  expression  of  autotaxin  
compared  with  59/73  (80.0%)  of  pT2.    While  4/146  (2.7%)  of  pTa  showed  
strong  expression  compared  with  9/73  (12.3%)  of  pT2.    A  p-­‐‑value  of  0.028  was  
achieved  suggesting  a  significant  association  between  autotaxin  expression  
and  stage  of  disease.  However  there  was  no  significant  trend  towards  
stronger  staining  with  higher  stages  (test  for  trend  p=0.083)  as  one  might  
expect  and  the  effect  disappeared  when  strong  and  weak  staining  are  
combined  (p=0.165).  
  










Stage   pTa   Count   128   14   4   146  
      %  within  
stage  
87.7%   9.6%   2.7%   100.0%  
   pT1   Count   71   3   4   78  
      %  within  
stage  
91.0%   3.8%   5.1%   100.0%  
   pT2   Count   59   5   9   73  
      %  within  
stage  
80.8%   6.8%   12.3%   100.0%  
Total      Count   258   22   17   297  
      %     86.9%   7.4%   5.7%   100.0%  
Table  3.3.N  Autotaxin  Expression  in  Tumour  vs.  Stage.  
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I  then  tested  for  an  association  between  autotaxin  staining  and  grade  of  
tumour  however  no  significant  association  (p=0.487)  or  trend  (p=0.577)  
between  tumour  grade  and  autotaxin  expression  was  found.  
  
When  testing  for  an  association  between  autotaxin  expression  and  muscle  
invasion  199/244  (88.8%)  of  the  NMI  group  showed  no  expression  compared  
with  59/73  (80.8%)  of  MI  tumours.  8/224  (3.6%)  of  NMI  showed  strong  
expression  compared  with  9/73  (12.3%)  of  MI.  
The  association  (p=0.020)  and  trend  (p=0.016)  was  found  to  be  significant  
(Table  3.3.2.B).    However  it  was  no  longer  significant  if  strong  and  weak  
expression  were  combined  (p=0.078)  but  was  strengthened  if  weak  and  
negative  expression  were  combined  (p=0.009),  indicating  that  the  degree  of  
tumour  expression  is  important.    This  shows  that  even  within  the  expanded  
cohort,  autotaxin  may  be  an  important  prognostic  marker  of  poor  prognosis  
of  bladder  cancer.  
  










NMI   Count   199   17   8   224  
   %  within  
NMI  
88.8%   7.6%   3.6%   100.0%  
MI   Count   59   5   9   73  
   %  within  
MI  
80.8%   6.8%   12.3%   100.0%  
Total   Count   258   22   17   297  
   %     86.9%   7.4%   5.7%   100.0%  
Table  3.3.O  Autotaxin  Expression  vs.  Muscle  Invasion.    
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NMI   Count   199   25   224  
   %  within  
NMI  
88.8%   11.2%   100.0%  
MI   Count   59   14   73  
   %  within  
MI  
80.8%   19.2%   100.0%  
Total   Count   258   39   297  
   %     86.9%   13.1%   100.0%  
Table  3.3.P  Autotaxin  Expression  vs.  Muscle  Invasion.  p=0.078  
  
  







NMI   Count   216   8   224  
   %  within  
NMI  
96.4%   3.6%   100.0%  
MI   Count   64   9   73  
   %  within  
MI  
87.7%   12.3%   100.0%  
Total   Count   280   17   297  
   %   94.3%   5.7%   100.0%  
Table  3.3.Q  Autotaxin  Expression  vs.  Muscle  Invasion.  p=0.009  
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3.3.2.2  Association  between  Autotaxin  Expression  in  Vessels,  compared  with  
Expression  in  Tumour  
  
Whether  or  not  there  was  a  link  between  autotaxin  staining  of  the  vessels  and  
of  the  tumour  was  also  considered.  However  there  was  no  evidence  found  to  
support  such  a  correlation.  Chi-­‐‑  square  test  (p=0.083)  indicates  no  association,  
and  the  Kappa  statistic  of  0.024  indicates  poor  agreement  between  autotaxin  
expression  in  tumour  and  vessels.    
  












None   Count     82   99   94   275  
      %  of  total   26.0%   31.4%   29.8%   87.3%  
   Weak   Count   3   8   12   23  
      %  of  total   1.0%   2.5%   3.8%   7.3%  
   Strong   Count   6   2   9   17  
      %  of  total   1.9%   0.6%   2.9%   5.4%  
Total      Count   91   109   115   315  
      %  of  total   28.9%   34.6%   36.5%   100%  
Table  3.3.R  Association  between  Autotaxin  Expression  in  Vessels,  compared  
with  Expression  in  Tumour  
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The  tests  previously  performed  for  autotaxin  tumour  expression  in  the  pilot  
cohort  were  then  repeated  on  the  expanded  cohort  for  vessel  expression  and  
no  association  was  found  between  autotaxin  vessel  staining  and  grade  
(p=0.351),  stage  (p=0.420)  or  muscle  invasiveness  (p=0.158).  
  










Stage   pTa   Count   43   48   55   146  
      %  within  stage   29.5%   32.9%   37.7%   100.0%  
   pT1   Count   19   26   33   78  
      %  within  stage   24.4%   33.3%   42.3%   100.0%  
   pT2   Count   22   31   21   74  
      %  within  stage   29.7%   41.9%   28.4%   100.0%  
Total      Count   84   105   109   298  
      %  within  stage   28.2%   35.2%   36.6%   100.0%  
Table  3.3.S  Autotaxin  Expression  in  Stage  vs.  Vessels.  P=0.420  
  










Grade   G1   Count   21   19   29   69  
      %  within  stage   30.4%   27.5%   42.0%   100.0%  
   G2   Count   20   26   32   78  
      %  within  stage   25.6%   33.3%   41.0%   100.0%  
   G3   Count   44   59   47   150  
      %  within  stage   29.3%   39.3%   31.3%   100.0%  
Total      Count   85   104   108   297  
      %  within  stage   28.6%   35.0%   36.4%   100.0%  
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NMI   Count   64   73   88   225  
      %  within  
NMI  
28.4%   32.4%   39.1%   100.0%  
   MI   Count   21   31   20   72  
      %  within  MI   29.2%   43.1%   27.8%   100.0%  
Total      Count   85   104   108   297  
      %     28.6%   35.0%   36.4%   100.0%  
Table  3.3.U  Autotaxin  Expression  in  Vessels  vs.  Muscle  Invasiveness.  P=0.158  
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3.3.2.3  The  Association  between  Autotaxin  Expression  and  Survival/Event-­‐‑
Free  Survival  
As  the  data  demonstrated  a  possible  association  between  expression  of  
autotaxin  and  muscle  invasiveness,  I  looked  at  whether  this  effect  of  autotaxin  
expression  impacted  on  survival.  However  there  was  no  significant  effects  of  
autotaxin  tumour  expression  on  survival.  
No  significant  association  was  found  between  degree  of  staining,  strong/weak  
compared  with  none,  and  overall  survival  in  months  (p=0.944)  (Figure  3.1).  
  
  
Figure  3.1  –  Kaplan-­‐‑Meier  plot  showing  the  association  between  autotaxin  
expression  and  survival/event-­‐‑free  survival  (y  axis).  Overall  survival  in  




	   58	   	  
  
Staining   5-­‐‑Year  
Survival  
95%  CI   No.  Subjects   No.  
Deaths  
Strong  or  Weak   66.5%   50.6%  to  82.5%   40   13  
None   68.1%   62.3%  to  73.9%   275   87  
Table  3.3.V–  The  Association  between  Autotaxin  Expression  and  
Survival/Event-­‐‑Free  Survival  in  Months.    
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Similarly,  I  found  no  significant  association  found  between  degree  of  staining  
and  event  free  survival  in  months  (p=0.724)  (Figure  3.2).  
  
  
Figure  3.2  –  Kaplan-­‐‑Meier  plot  of  event-­‐‑free  survival  in  months  (x  axis).  
Cumulative  survival  in  %  (y  axis),  P=0.724  
(Events  =  first  record  of  either  disease  recurrence,  disease  progression  or  death)  
  
  
Staining   5-­‐‑Year  EFS   95%  CI   No.  Subjects   No.  Events  
Strong  or  
Weak  
44.6%   28.4%  to  
60.9%  
40   22  
None   46.1%   40.1%  to  
52.1%  
275   147  
Table  3.3.W  –  Table  3.3.2.5  –  Strong  or  Weak  Staining  versus  None;  Event  Free  
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Events   Strong  or  Weak  Staining   No  Staining  
Disease  Progression   4  (18%)   28  (19.0%)  
Disease  Recurrence   8  (36%)   60  (40.8%)  
Death  without  
Progression/Recurrence  
10  (46%)   59  (40.1%)  
Table  3.3.X  –  Disease  Progression  and  Recurrence  Free  Survival     
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3.3.2.3.1  Strong  Staining  versus  Weak  or  None  
The  association  of  autotaxin  with  survival  was  then  considered  after  grouping  
staining  into  ‘strong’  versus  ‘weak  or  none’  staining.  
Despite  the  small  numbers,  there  was  a  suggestion  of  poorer  survival  in  
strong  stainers.  This  most  probably  resulted  from  the  association  of  staining  
with  higher  disease  stage.  
  
Figure  3.3  –  Kaplan-­‐‑Meier  plot  of  overall  survival  in  months  (x  axis).  
Cumulative  survival  as  %  (y  axis).  P=0.120  
The  sudden  drop  of  the  survival  curve,  seen  in  graph  3.3,  after  80  months  is  
an  artifact  caused  by  the  death  of  the  subject  with  the  longest  follow-­‐‑up  time.    
  
Staining   5-­‐‑Year  
Survival  
95%  CI   No.  Subjects   No.  Deaths  
Strong     48.5%   22.2%  to  
74.8%  
17   8  
None/Weak   68.9%   63.4%  to  
74.5%  
298   92  
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Table  3.3.Y  –  Strong  Staining  versus  Weak/None;  Overall  Survival  
The  censor  date  was  therefore  re-­‐‑set  to  28/2/2013  rather  than  31/12/2012,  
thereby  increasing  the  follow-­‐‑up  time  and  eliminating  the  sudden  drop  of  the  
survival  curve  as  can  be  seen  in  figure  3.4.  




Figure  3.4  –  Kaplan-­‐‑Meier  plot  of  overall  survival  in  months  (x  axis).  
Cumulative  survival  as  %  (y  axis).  p=0.145  –Log-­‐‑rank  Test  (for  equality  of  
survival  curves)  
  
Staining   5-­‐‑Year  
Survival  
95%  CI   No.  Subjects   No.  Deaths  
Strong   48.5%   22.2%  to  74.8%   17   8  
Weak  or  None   68.8%   63.3%  to  74.3%   298   96  
Table  3.3.Z  –  Overall  Survival  in  Months  with  Increased  Follow-­‐‑up  data  
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The  difference  in  survival  is  still  not  statistically  significant,  however  some  
late  deaths  still  occur  in  the  ‘none/weak’  staining  group.    
Some  survival  times  for  the  live  cases,  which  are  a  measure  of  quality  of  
follow-­‐‑up,  are  shown  below  in  table  3.3.3.    Minimum  survival  in  months  for  
the  ‘strong’  staining  group,  including  9  cases  only,  is  41.09  while  maximum  
survival  is  68.22  months.  This  is  compared  with  the  ‘weak  or  none’  staining  
group,  including  202  cases,  in  which  minimum  survival  in  months  is  29.24  
and  maximum  survival  is  85.53  months.  
  
Staining   No.  Cases   Minimum     Medium   Maximum  
Strong   9   41.09   54.802   68.22  
Weak  or  None   202   29.24   58.52   85.53  
Table  3.3.1.A  -­‐‑  Follow-­‐‑Up  Time  in  Months  (Survival  Time  for  Live  Cases  
Only)  
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The  “pattern  of  censoring”  for  the  two  groups  is  illustrated  in  graph  3.5  
below.  There  appears  to  be  no  obvious  difference  in  the  quality  of  follow-­‐‑up,  
but  the  non-­‐‑staining  group  does  appear  to  have  a  longer  follow-­‐‑up.    
  
Figure  3.5  –  Pattern  of  Censoring  for  the  2  groups  of  strong  staining  (2.00)  vs  
weak/none  (1.00),  across  survival  in  months.  
  
To  elucidate  further  whether  or  not  longer  follow-­‐‑up  time  for  the  none/weak  
staining  group  has  affected  the  results,  follow-­‐‑up  time  can  be  truncated  at  69  
months,  i.e.,  any  subjects  with  longer  follow-­‐‑up  then  69  months  are  classed  as  
“alive”  at  69.00  months.  
However,  the  p-­‐‑value  remains  unchanged  at  p=0.145.  
Considering  event-­‐‑free  survival  there  was  no  significant  association  found  
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Figure  3.6  –  Event-­‐‑Free  Survival  in  Months  against  cumulative  survival  as  %,  
p=0.720    
  
Staining   5-­‐‑Year  EFS   95%  CI   No.  Subjects   No.  Events  
Strong     37.6%   12.5%  to  
62.8%  
17   10  
Weak  or  
None  
46.2%   40.3%  to  
52.0%  
298   159  
Table  3.3.1.B–  Increasing  Follow-­‐‑Up  –  Overall  Survival  in  Months  
  
Events   Strong  Staining   Weak  or  None  
Disease  Progression   1  (10%)   31  (19.5%)  
Disease  Recurrence   3  (30%)   65  (40.9%)  
Death  without  
Progression/Recurrence  
6  (60%)   63  (39.6%)  
Table  3.3.1.C  –  Increasing  Follow-­‐‑Up  –  Disease  Progression/Recurrence  in  
Months  
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3.3.2.4.  The  Association  of  Disease  Stage  (Muscle  Invasive  or  Non-­‐‑
Muscle  Invasive)  and  Disease  Progression.  
  
BCPP  defines  “progression’  as  tumour  recurring  at  a  higher  stage  or  grade  
than  the  original.  Alternatively,  the  “standard”  definition  describes  
progression  when  a  tumour  becomes  muscle-­‐‑invasive,  the  original  having  
been  non-­‐‑invasive  (pTa  and  pT1)).    
  
3.3.2.4.1  Progression-­‐‑Free  Survival  versus  Autotaxin  Staining  
Using  the  BCPP  definition  of  progression,  figure  3.7  shows  progression-­‐‑free  
survival  in  months  in  280  none/weakly  staining  patients  (who  experienced  36  
(13%)  disease  progression  events)  and  17  strongly  staining  patients  (who  
experienced  1  (6%)  disease  progression  events).    
The  strongly  staining  subjects  appear  to  have  fewer  progressive  events,  but  
the  log-­‐‑rank  test  for  equality  of  survival  indicates  no  difference  (p=0.455).    
Five-­‐‑year  progression-­‐‑free  survival  is  93.8%  (95%  CI  81.9%-­‐‑100%)  for  the  
‘strong’  staining  group  and  only  84.55%  (95%  CI  79.7  to  89.3%)  for  the  
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When  considering  only  non-­‐‑invasive  tumours  (pTa  and  pT1),  which  included  
224  subjects  and  disease  progression,  the  association  was  not  significant  with  
a  p=0.280,  as  shown  in  Figure  3.8.  
  
  
Figure  3.8  –  Progression  free  survival  in  months  in  non-­‐‑invasive  tumours  
(pTa  and  pT1),  p=0.280  
  
  
When  considering  only  muscle-­‐‑invasive  tumours  (pT2)  (73  subjects)  and  




Figure  3.9  –  Progrssion  free  survival  in  months  in  muscle-­‐‑invasive  tumours  
(pT2),  p=0.985  
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Therefore,  using  the  BCPP  definition  of  progression,  there  was  no  association  
between  autotaxin  expression  and  progression-­‐‑free  survival  although  the  
strongly  staining  group  does  appears  to  have  fewer  progression  events.  
The  effect  is  similar  when  considering  the  standard  definition  of  progression.  
Figure  4.0  shows  a  progression-­‐‑free  survival  in  months  for  216  ‘none/weakly’  
staining  patients  who  experienced  6  (2.8%)  events  (progressions)  and  8  
‘strong’  staining  patients  who  had  no  events.    
Again  ‘strong’  autotaxin-­‐‑staining  in  the  tumour  appears  inversely  linked  to  
progression  but  the  log-­‐‑rank  test  for  equality  of  survival  indicated  no  
difference  (P=0.642).  
Five  year  progression-­‐‑free  survival  is  100%  (95%  CI  not  calculable)  for  the  
‘strong’  staining  group  and  97.6%  (95%  CI  95.6  to  99.7%))  for  the  




Figure  3.10  –  Progression  free  survival  in  months  in  224  pTa  and  pT1  Patients.  
  
	   70	   	  
3.4  Illustration  of  Autotaxin  Expression  in  Bladder  Cancer  
  
  
Figure  3.11.  Tumour  cells  showing  weak  cytoplasmic  expression  of  autotaxin  
in  bladder  cancer  
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Figure  3.12.  Tumour  cells  showing  strong  cytoplasmic  expression  of  autotaxin  
in  bladder  cancer  
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Figure  3.14.  Vessels  strong  for  autotaxin  expression  in  bladder  cancer  
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Table  3.5A-­‐‑  Gender  of  the  initial  cohort  (124)  
  
  
Table  3.5B-­‐‑  Gender  of  the  expanded  cohort  (15)  
  
Gender  distribution  was  similar  for  the  two  groups.  In  the  initial  cohort  26.6%  
were  female  compared  with  73.4%  male.  In  the  expanded  cohort  21.9%  were  




Table  3.5C-­‐‑  Marital  status  in  the  initial  cohort  
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Table  3.5D-­‐‑  Marital  status  in  the  expanded  cohort  
  
37.1%  of  the  initial  cohort  were  not  married  and  58.1%  were  married  or  
cohabiting.  36.5%  of  the  expanded  cohort  were  not  married  as  compared  with  




     
  Table  3.5E-­‐‑  Ethnicity  of  the  initial  cohort  
  
  
Table  3.5F-­‐‑  Ethnicity  of  the  expanded  cohort  
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91.2%  of  the  initial  cohort  were  classed  as  white  and  3.2%  as  non-­‐‑white  
ethnicity.  
95.2%  of  the  expanded  cohort  were  classed  as  white  and  1.9%  as  non-­‐‑white.  











Table  3.5G-­‐‑  Smoking  status  of  the  expanded  cohort  
  
22.6%  of  the  initial  cohort  had  never  smoked,  55.6%  were  ex-­‐‑smokers  and  
16.1%  were  smokers.  
19.7%  of  the  expanded  cohort  had  never  smoked,  54.3%  were  ex-­‐‑smokers  and  
22.5%  were  smokers.  
There  was  a  larger  percentage  of  smokers  in  the  expanded  cohort  but  
comparable  figures  of  never  smoked  and  ex-­‐‑smokers.  
  
Therefore  the  initial  and  expanded  cohorts  appear  similar  in  terms  of  gender,  
ethnicity,  marital  status  and  smoking  status.  
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3.6  Discussion  
  
At  the  onset  of  this  piece  of  work  there  had  been  little  work  done  on  the  
association  between  autotaxin  expression  and  bladder  cancer.  A  literature  
review  revealed  a  study  by  Lee  et  al.  (2007),  in  which  an  association  of  the  
LPA6  receptor  with  familial  bladder  cancer  was  reported.  LPA6,  previously  
known  as  P2RY5,  couples  to  the  Gα13-­‐‑RHoA  signaling  pathway  which  has  a  
regulatory  role  with  the  actin  cytoskeleton.  The  expression  of  the  gene  P2RY5  
can  be  induced  by  T  cell  activation  (Kaplan  et  al.  1993)  as  well  as  in  LPA-­‐‑
stimulated  fibroblasts  (Stortlers  et  al.  2008)(Houben  et  al.  2011).  Crawford  et  
al.  (2008)  suggested  that  LPA6/P2RY5  could  represent  a  potential  risk  marker  
for  bladder  cancer.  
  
However  with  the  growing  interest  in  the  role  of  the  autotaxin-­‐‑LPA  signaling  
pathway  in  tumour  growth  and  invasion,  and  angiogenesis,  other  groups  
started  focusing  on  this  pathway.  
  
More  recently,  Kataoka  et  al.  (2014)  found  that  LPA1  mRNA  expression  was  
significantly  increased  in  muscle  invasive  bladder  cancer  samples  than  non-­‐‑
muscle  invasive  samples,  and  strong  LPA1  expression  was  found  on  cell  
membranes  in  muscle  invasive  samples.  They  also  reported  that  LPA  
treatment  resulted  in  an  increase  in  T24  cell  invasion  while  treatment  with  
LPA1    siRNA  or  LPA1    inhibitor  decreased  cell  invasion.    They  concluded  that  
LPA  signaling  and  LPA1  activation  in  particular  promoted  bladder  cancer  
invasion  and  suggested  that  LPA1  could  be  used  to  identify  bladder  cancers  
with  high  invasive  potential  and  furthermore  could  itself  be  used  as  a  
therapeutic  target  in  the  treatment  of  invasive  bladder  cancer.  
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Work  in  this  chapter  has  made  two  interesting  observations.  
First,  a  significant  association  between  stage  of  bladder  cancer  and  higher  
expression  of  autotaxin.  Second,  an  association  between  autotaxin  expression  
and  disease  progression.      
As  advancing  stage  of  disease  normally  corresponds  with  poorer  prognosis,  
identifying  autotaxin  expression  in  newly  diagnosed  bladder  cancers  could  in  
the  future  be  used  as  a  marker  of  poor  prognosis.    Furthermore,  inhibitors  of  
autotaxin  could  play  a  role  in  modifying  the  disease.  For  example,  Benesch  et  
L.  2014,  found  that  a  new  autotaxin  inhibitor  called  ONO-­‐‑8430506  decreased  
initial  lung  tumour  growth  and  subsequent  metastatic  nodules  both  by  60%  
compared  with  control  mice.    If  inhibitors  of  autotaxin  were  found  to  have  a  
similar  effect  in  bladder  cancer  then  current  treatments  of  bladder  cancer  
could  be  avoided  along  with  their  side  effects.  
That  said,  monitoring  the  side  effects  of  autotaxin  inhibitors  will  also  be  
crucial.  Although  no  autotaxin/LPA-­‐‑targeting  cancer  drugs  are  available  for  
clinical  use  at  present,  development  is  progressing  rapidly  (Tabuchi  et  al.  
2015).  There  is  however  a  report  of  LPA1    deficiency  resulting  in  schizophrenia  
type  pathology  in  mice  (Harrison  et  al.  2003).  
  
Weaknesses  of  the  current  study  include  small  sample  size  as  well  as  the  
absence  of  normal  bladder  mucosa  with  which  to  compare  autotaxin  
expression.    However  obtaining  samples  of  truly  ‘normal’  bladder  is  
extremely  difficult.  Even  sections  of  normal  bladder  mucosa  taken  from  a  
bladder  which  has  cancer  elsewhere  would  be  expected  to  exhibit  a  degree  of  
field  change.  
Future  work  would  involve  increasing  the  cohort  number,  assessing  autotaxin  
expression  in  normal  bladder  mucosa  and  comparing  it  with  that  of  
expression  in  bladder  cancer.    
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As  muscle  invasive  bladder  cancer  is  associated  with  a  higher  mortality  than  
non  muscle  invasive  bladder  cancer  it  would  be  interesting  to  further  tease  
out  differences  in  expression  between  NMI  and  MI  bladder  cancer  to  
ascertain  if  there  is  a  potential  role  of  autotaxin  in  MI  bladder  cancer.  
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Expression  of  Autotaxin  in  a  Cohort  of  
Metastatic  Renal  Cancer  Patients  
Treated  with  Sunitinib  
  
4.1  Introduction  
Renal  cell  carcinoma  (RCC)  represents  2-­‐‑3%  of  all  cancers  worldwide,  with  
the  western  nations  demonstrating  the  highest  incidence  (European  Network  
of  Cancer  Registries).    Incidence  of  renal  cell  carcinoma  has  increased  by  
approximately  2%  over  the  last  11  years  both  worldwide  and  in  Europe,  
however  rates  in  Sweden  and  Denmark  have  gradually  fallen  (Lindblad  et  al.    
2004).    
In  Europe  alone,  there  were  estimated  to  have  been  84,400  new  cases  of  RCC  
and  43,700  kidney  related  deaths  in  2012  (Ferlay  et  al.  2013).  
There  are  different  types  of  RCC,  each  with  different  histo-­‐‑pathological  and  
genetic  features.    There  is  a  1.5:1  male  predominance  and  a  peak  incidence  of  
between  60  and  70  years.    
Risk  factors  include  smoking,  obesity,  hypertension  (Lipworth  et  al.  2006)  as  
well  as  having  a  first-­‐‑degree  relative  with  RCC  (Clague  et  al.  2009).  
The  evidence  as  yet  does  not  support  a  strong  link  between  dietary  habits  and  
exposure  to  specific  carcinogens.    Smoking  cessation  and  preventing  obesity  
have  been  found  to  be  associated  with  reduced  risk,  as  has  moderate  alcohol  
consumption  (Bellocco  et  al.  2012,  Song  et  al.  2012).  
Over  50%  of  RCC  are  detected  incidentally  by  ultrasound  (US)  or  computed  
tomography  (CT).    However,  these  tumours  tend  to  be  smaller  and  of  lower  
stage  (Patard  et  al.  2002,  Kato  et  al.  2004,  Tsui  et  al.  2000).  
  
Treatment  options  for  RCC  differ  depending  on  stage.  For  localised  disease,  
surgery  is  the  only  curative  option.  Alternatives  to  surgery  include  the  
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ablative  therapies  such  as  cryoablation  and  radiofrequency  ablation.    For  
locally  advanced  disease,  i.e.,  lymph  node  involvement  or  venous  thrombosis,  
surgery  remains  an  option  but  often  neo-­‐‑adjuvant  treatments  are  also  
considered  however  the  evidence  from  randomized  controlled  trials  has  yet  
to  be  reported.  
Treatment  for  advanced/metastatic  RCC  involves  cytoreductive  surgery,  local  
therapy  to  metastases  such  as  radiotherapy  to  bone  metastases,  or  systemic  
therapies.  Systemic  therapies  include  chemotherapy,  targeted  therapies  such  
as  the  tyrosine  kinase  inhibitor  monoclonal  antibody  against  VEGF  or  mTOR  
inhibitors  such  as  temsirolimus  or  everolimus,  and  in  selected  cases  
immunotherapy  such  as  interleukin-­‐‑2.  
Sunitinib  is  a  multi-­‐‑targeted  tyrosine  kinase  inhibitor  (TKI).    It  predominately  
targets  the  vascular  endothelial  growth  factor  receptor  (VEGFR)  and  is  used  
as  the  first  line  therapy  for  advanced  and/or  metastatic  renal  call  carcinoma.    
Most  patients  develop  resistance  to  Sunitinib  after  one  year  while  some  
appear  to  have  an  innate  resistance  and  do  not  respond  at  all  (Motzer  et  al.  
2009).  Resistance  is  marked  by  renewed  angiogenesis  and  disease  
progression.  
Whether  open  or  laparoscopic  surgery,  the  risks  posed  are  the  same  general  
risks  as  for  any  major  surgery  as  well  as  risks  specific  to  nephrectomies  such  
as  renal  failure,  pneumothorax,  etc.  The  side  effects  associated  with  systemic  
treatment  comprise  nausea,  vomiting,  diarrhoea,  hypertension  and  hand  and  




     
	   82	   	  
There  are  many  treatments  available  for  RCC  but  none  are  satisfactory.    
Since  one  of  the  main  functions  of  LPA  is  angiogenesis,  and  aberrant  
angiogenesis  has  been  found  to  be  a  contributory  factor  in  the  development  of  
RCC  (Su  et  al.  2013),  then  autotaxin  and  the  LPA  signaling  pathway  represent  
a  potential  therapeutic  target  in  the  treatment  of  renal  cancer.  At  present  there  
is  little  known  about  the  role  of  autotaxin  and  LPA  in  renal  cancer.  
This  chapter  will  describe  the  expression  of  autotaxin  in  the  tumours  of  a  
cohort  of  patients  with  renal  cancer.    
  
4.2  Materials  and  Methods  
New  sections  were  made  from  paraffin  embedded  blocks  available  from  the  
renal  cohort.  An  antibody  targeting  autotaxin  was  validated  using  tonsil  and  
was  then  used  to  study  autotaxin  expression  in  these  tumours.  
Immunohistochemistry  was  performed  using  the  methods  set  out  in  the  
materials  and  methods  chapter.  
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4.3  Results  
The  sample  size  of  this  cohort  was  small  and  as  a  result  it  was  not  possible  to  
analyze  the  data  using  the  same  statistical  tests  as  had  been  used  for  the  
bladder  work.  
  
4.3.1  Cohort  Characteristics  
The  subject  characteristics  of  the  cohort  itself  were  considered  and  are  
illustrated  below.  By  comparing  characteristics  of  the  present  cohort  with  
national  figures  published  by  Cancer  Research  UK  for  the  time  period  2009-­‐‑
2011  it  can  be  determined  whether  or  not  the  present  cohort  is  a  
representative  sample.  
  
There  were  59  patients  in  the  cohort,  45  (76%)  male  and  14  (24%)  female.  
Similarly,  incidence  rates  nationally  are  higher  for  males  than  for  females  at  
age  35  and  above  (the  gap  is  not  significant  in  younger  age  groups),  and  this  
gap  is  widest  at  85+,  when  the  male:  female  incidence  ratio  of  age-­‐‑specific  
rates  (to  account  for  the  different  proportions  of  males  to  females  in  each  age  
group)  is  around  2.1:1.  
  
Comparing  age  distribution  in  the  present  cohort  (figure  4.2)  with  national  
figures  (figure  4.1)  a  similar  distribution  can  be  seen.    Age-­‐‑specific  incidence  
rates  rise  sharply  from  around  age  40-­‐‑  50,  peaking  in  the  60-­‐‑  70  age  group.  
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Figure  4.1  Kidney  Cancer  2009-­‐‑2011.  Taken  from  Cancer  Research  UK.  
Average  number  of  new  case  per  year  and  age-­‐‑specific  incidence  rates  per  
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Figure  4.2  Age  distribution  of  Renal  Cohort  
  
The  median  age  of  the  cohort  at  diagnosis  was  60  years  (range  34-­‐‑85  years).  
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Stage  at  diagnosis  was  similar  between  the  cohort  and  national  figures  for  
stage  I  and  II  but  differed  for  stage  III,  IV  and  cases  where  stage  was  not  
known  (Table  4A).  The  present  study  cohort  included  only  metastatic  renal  
cancer  and  hence  percentage  of  cases  which  were  stage  3  (68.6%)  is  higher  in  
the  study  cohort  than  that  observed  nationally.  
  
  
Stage  at  Diagnosis   %  of  Cases  –  Present  
Study  Cohort  
%  of  Cases  –  England  
2012  
Stage  I   17.6   15.7  
Stage  II   3.9   3.8  
Stage  III   68.6   8.4  
Stage  IV   5.9   15.3  
Stage  not  known   3.9   56.8  
Table  4A.  Proportion  of  kidney  cancer  diagnosed  at  each  stage,  all  ages,  in  the  
present  cohort  compared  with  figures  in  England  in  2012  (Cancer  Research  
UK,  2010)  
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Time  from  diagnosis  to  trial  entry  was  considered  and  is  illustrated  in  Figure  
4.1A  and  4.1B  below.  The  mean  time  from  diagnosis  to  trial  entry  was  22.6-­‐‑






Figure  4.1A                                 Figure  4.1B  
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Survival  was  recorded  from  the  date  of  trial  entry  to  the  date  of  death  (43  
patients)  or  the  date  last  seen  alive  (16  patients).  The  survival  curve  is  
illustrated  in  Figure  4.1D  below.  
  
  
Figure  4.1D  Kaplan  Meier  plot  showing  date  of  trial  entry  until  death  in  months  (x)  
vs.  cumulative  survival  (%)  (y)  
  
1-­‐‑year  survival  rate  was  81.4%  (95%  CI  71.4  to  91.3),  
3-­‐‑year  survival  rate  was  37.3%  (95%  CI  24.9  to  49.6)  and  5-­‐‑year  survival  rate  
was  27.2%  (95%  CI  14.5  to  39.9).  Therefore,  survival  dropped  substantially  
with  time  in  this  cohort.  Median  survival  was  24.67  months  (95%  CI  16.19-­‐‑
33.15).  
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However,  comparing  these  results  with  national  statistics,  1-­‐‑year  survival  is  
similar  but  5-­‐‑year  survival  nationally  is  much  higher;  56.2%  compared  with  
27.2%.  
  












Net  Survival   81.4   72.4   27.2   56.2  
95%  LCI   71.4   72.3   14.5   56.0  
95%  UCI   91.3   72.4   39.9   56.4  
Table  4B  Comparing  1  and  5-­‐‑year  survival  rates  between  the  cohort  and  
adults  (age  15-­‐‑99),  England  and  Wales,  2010-­‐‑2011.  
LCI-­‐‑  lower  confidence  interval,  UCI-­‐‑  upper  confidence  interval.  
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Disease  progression  can  be  defined  as  any  change  in  the  disease  such  that  it  
becomes  more  severe.  This  may  involve  worsening  grade  or  stage  of  the  
disease,  increase  in  tumour  volume  or  new  diagnosis  of  metastases.    
In  the  present  study  disease  progression  was  seen  in  48  cases.  There  were  no  
patients  who  died  without  disease  progression.  
  
  
Figure  4.1E  Progression-­‐‑free  survival  in  months  vs.  cumulative  survival  (%).  
  
1  year  progression-­‐‑free  survival  rate  was  61.0%  (95%  CI  48.6  to  73.5).  3  year  
progression-­‐‑free  survival  rate  was  32.2%  (95%  CI  20.3  to  44.1)  and  5  year  
progression-­‐‑free  survival  rate  was  23.0%  (95%  CI  11.4  to  34.6).  
Median  progression  free  survival  was  19.57  months  (95%  CI  9.59-­‐‑29.55).  
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4.3.2  Association  of  Autotaxin  Expression  and  Survival  in  Metastatic  Renal  Cell  
Carcinoma  
  
Sections  from  45  subjects  in  the  cohort  were  stained  for  autotaxin.  Specimens  
were  excluded  from  14  subjects  due  to  poor  quality  paraffin  blocks.  
Expression  of  autotaxin  in  vessels  was  reported;  all  tumour  tissues  stained  
negative  for  autotaxin  expression.  
The  effect  of  autotaxin  expression  on  survival  was  considered  initially.  
  
Comparing  autotaxin  expression  in  all  groups  individually,  none,  weak  and  
strong,  no  significant  association  with  survival  was  found  (p=0.689).  
  
  
Figure  4.2A  –  Survival  in  months  vs.  cumulative  survival  (%)  in  all  three  
groups;  none  (n=6)  vs.  weak  (N=9)  vs.  strong  (N=30).        
p=0.689  
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Grouping  the  no  autotaxin  expression  and  weak  groups  together  and  






Figure  4.2B  –  Survival  in  months  vs.  cumulative  survival  (%)  for  none  or  weak  
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Comparing  the  no  autotaxin  expression  group  with  the  weak  and  strong  





Figure  4.2C  –  Survival  in  months  vs.  cumulative  survival  (%)  for  none  (n=6)  




Therefore  the  level  of  autotaxin  expression  (in  vessels)  was  not  found  to  
influence  survival,  and  grouping  the  weak  staining  cases  with  either  the  
negative  or  the  strongly  staining  cases  did  not  alter  the  findings.  
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Figure  4.2D-­‐‑Time  to  disease  progression  in  months  vs.  cumulative  survival  
(%)  in  groups  none  (N=6),  weak  (N=9)  and  strong  (N=30).        
     
p=0.566  
  
Comparing  autotaxin  expression  in  all  groups  individually,  negative,  weak  
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Grouping  the  no  autotaxin  expression  and  weak  groups  together  and  
comparing  with  strong,  no  significant  association  with  time  to  disease  




Figure  4.2E-­‐‑  Time  to  disease  progression  in  months  vs.  cumulative  survival  
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Comparing  the  no  autotaxin  expression  group  with  the  weak  and  strong  





Figure  4.2F-­‐‑  Time  to  disease  progression  in  months  vs.  cumulative  survival  
(%)  in  groups  none  (N=6)  and  weak  or  strong  (N=39).        
p=0.531  
  
Therefore,  similarly,  the  level  of  autotaxin  expression  did  not  affect  time  to  
progression;  grouping  the  weak  staining  cases  with  either  the  negative  or  the  
strongly  staining  cases  did  not  alter  the  findings.  
It  is  worth  noting  that,  although  not  statistically  significant,  the  high  level  
expression  of  autotaxin  found  on  the  tumour  associated  vasculature  was  not  
apparent  in  the  blood  vessels  of  a  small  number  of  matched  normal  renal  
tissue  that  were  tested.  
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4.3.3  Multivariate  survival  analysis  (Time  to  death)  
  
Multivariate  survival  analysis  was  performed  using  histology  date  as  the  
fixed  starting  point  and  ‘time  to  death’  as  the  terminating  event.  
As  the  cohort  in  this  study  was  small,  only  limited  multivariate  modeling  
could  be  employed.  
Models  with  more  than  2  variables  are  likely  to  be  unreliable,  so  bivariate  Cox  
proportional  hazards  regression  was  used  to  determine  if  autotaxin  is  of  
prognostic  significance  in  the  presence  of  these  other  factors.    





Age  in  years  (continuous  variable)  
   Gender    
   Disease  grade  (1  &  2  vs.  3  vs.    4)  
   T-­‐‑stage  ((T1  &  T2  vs.  T3  &  T4)  
   N-­‐‑stage  (N0  vs.  N1&N2  vs.Nx)  
   Heng  Score  (Good  vs.  Intermediate  vs.  poor)    
(The  Heng  score  is  a  prognostic  indicator  used  in  metastatic  
renal  cell  carcinoma.  The  factors  used  to  derive  the  Heng  score  
were  not  tested  individually.)  
   No.  metastatic  sites  (1  vs.  2  vs.  >2)  
   Sarcomatoid  factor  (present/absent)  
   CA9  (positive/negative)  CA9  is  over-­‐‑expressed  in  VHL  mutated  
clear  cell  renal  cell  carcinoma.  
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Marker   Co-­‐‑factor   Marker  
HR*  




ATX   -­‐‑   0.882   0.432  to  1.801   0.733   45  
ATX   Age     0.934   0.454  to  1.922   0.541   45  
ATX   Gender   0.883   0.432  to  1.802   0.942   45  
ATX   Grade     1.059   0.475  to  2.358   0.696   41  
ATX   T-­‐‑stage   1.179   0.534  to  2.606   0.405   38  
ATX   N  -­‐‑stage   1.217   0.554  to  2.671   0.925   39  
ATX   Heng  Score   0.740   0.341  to  1.606   0.158   45  
ATX   Metastasis  sites     0.776   0.350  to  1.719   0.730   45  
ATX   Sarcomatoid  
factor  
0.812   0.394  to  1.670   0.453   45  
ATX   CA9    (Pos  vs.  
Neg)  
0.846   0.407  to  1.757   0.317   44  
  
While  strong  autotaxin  staining  is  associated  with  a  slightly  lower  mortality  
risk  (hazard  ratio),  its  value  (0.882)  was  not  significantly  different  from  1.00  
(as  shown  by  the  confidence  interval  of  0.432  to  1.801).        
The  testing  of  all  other  factors  in  bivariate  models  did  not  produce  any  
significant  effect  for  autotaxin  –  neither  were  any  of  the  bivariate  models  
significantly  more  predictive  of  outcome  than  the  null  model  (i.e.  one  where  
no  factors  affect  survival).    Therefore  there  is  no  evidence  that  autotaxin  has  
any  prognostic  significance  in  RCC.    
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4.3.4  Multivariate  Survival  analysis  (Time  to  disease  progression)  
  
Multivariate  analysis  was  then  performed  using  histology  date  as  the  starting  
point  again  but  this  time  using  ‘time  to  disease  progression’  as  the  
terminating  event.  
  
Marker   Co-­‐‑factor   Marker  
HR*  




ATX   -­‐‑   0.906   0.447  to  1.837   0.786   45  
ATX   Age     0.942   0.461  to  1.924   0.734   45  
ATX   Gender   0.907   0.447  to  1.842   0.963   45  
ATX   Grade     0.987   0.439  to  2.219   0.920   41  
ATX   T-­‐‑stage   1.054   0.481  to  2.309   0.358   38  
ATX   N  -­‐‑stage   1.068   0.489  to  2.331   0.873   39  
ATX   Heng  Score   0.774   0.363  to  1.651   0.222   45  
ATX   Metastasis  sites     0.756   0.342  to  1.669   0.755   45  
ATX   Sarcomatoid  
factor  
0.843   0.410  to  1.735   0.666   45  
ATX   CA9    (Pos  vs.  
Neg)  
0.926   0.452  to  1.897   0.809   44  
  
Once  again  no  significant  association  was  found  between  autotaxin  
expression,  and  any  of  the  co-­‐‑factors  and  time  to  disease  progression.  
In  summary,  in  renal  cell  carcinoma,  autotaxin  does  not  appear  to  be  
associated  with  time  to  disease  progression,  however,  the  sample  size  was  
small.  
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4.4  Illustration  of  Autotaxin  Expression  in  Renal  cancer  
  
As  none  of  the  renal  cancer  tumours  were  positive  for  autotaxin,  expression  




Figure  4.4A.  Vessels  negative  autotaxin  expression  in  renal  cancer  
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Figure  4.4B.  Vessels  weak  autotaxin  expression  in  renal  cancer  
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Figure  4.4C.  Vessels  strong  autotaxin  expression  in  renal  cancer  
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4.5  Discussion  
  
This  study  focused  on  a  small  cohort  of  59  patients  with  metastatic  renal  cell  
carcinoma  treated  with  Sunitinib.    The  advantages  of  a  clinical  cohort  such  as  
this  one  was  the  excellent  follow  up  clinical  data.  Tissue  from  these  subjects  
was  stained  for  autotaxin  expression.      
Autotaxin  expression  in  vessels  only  was  reported  as  I  did  not  observe  any  
staining  in  tumour.  
There  was  no  significant  association  found  between  autotaxin  expression  and  
survival  or  time  to  disease  progression.  
Furthermore,  multivariate  analysis  found  that  autotaxin  had  no  prognostic  
significance  in  relation  to  renal  cell  carcinoma  and  no  association  with  time  to  
disease  progression.  
  
At  the  onset  a  literature  review  failed  to  identify  any  previous  work  on  the  
association  between  autotaxin  and  renal  cancer.  However,  in  2013  Su  et  al.  
reported  that  autotaxin  was  expressed  in  endothelial  cells  of  tumour  vessels  
but  not  in  the  tumour  cells,  confirming  the  findings  of  this  study.  They  also  
found  that  autotaxin  was  not  expressed  in  the  endothelial  cells  of  the  normal  
renal  capillaries,  again  similar  to  the  findings  of  this  study.  Interestingly,  they  
showed  that  endothelial  autotaxin  expression  in  renal  cell  carcinoma  was  
down  regulated  after  Sunitinib  treatment.  
  
Future  work  would  involve  expanding  the  current  cohort  as  any  significant  
associations  may  have  been  difficult  to  identify  with  such  small  numbers.    
It  would  also  be  interesting  to  compare  autotaxin  expression  in  renal  cell  
carcinoma  with  expression  in  pathologically  normal  renal  tissue.  However  it  
is  very  difficult  to  obtain  truly  normal  renal  tissue.  Specimens  from  
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nephrectomies  performed  for  benign  disease  are  likely  to  still  be  abnormal  
histologically  and  normal  tissue  from  a  cancerous  kidney  will  likely  
demonstrate  field  changes.    It  may  be  possible  to  identify  specimens  from  
renal  biopsies  performed  at  the  request  of  nephrologists  investigating  
nephrological  conditions.  
Comparing  autotaxin  expression  in  renal  cell  carcinoma  tumours  treated  with  
and  without  Sunitinib  would  also  be  another  interesting  study  to  establish  if  
Sunitinib  itself  affected  autotaxin  expression  as  the  study  by  Su  et  al.  (2013)  
suggests.  
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Discussion  
  
In  this  thesis  the  expression  of  autotaxin  in  relation  to  the  clinico-­‐‑pathological  
findings  of  the  two  urological  malignancies,  bladder  and  renal  cancer,  was  
evaluated.  
  
5.1  Bladder  Cancer  
5.1.1   Main  Findings  
I  found  that  in  bladder  cancer,  high-­‐‑level  expression  of  autotaxin  was  
significantly  associated  with  higher  stage  of  disease,  muscle  invasion  and  
disease  progression.  
Strong  autotaxin  expression  was  found  in  higher  stages  of  the  disease.  Higher  
stage  generally  refers  to  T2  disease,  the  stage  at  which  the  tumour  invades  the  
muscle  wall  of  the  bladder,  and  therefore  corresponds  to  muscle  invasive  
disease.    
This  is  a  potentially  important  finding  as  advancing  stage  of  disease/muscle  
invasion  generally  corresponds  with  poorer  prognosis.  Therefore,  if  autotaxin  
could  be  used  as  a  reliable  marker  of  higher  stage  disease  then  autotaxin  
inhibitors  could  have  a  potential  role  in  early  disease  modification  and  
preventing  subsequent  muscle  invasive  disease.  
  
5.1.2   Previous  Work  
A  literature  review  did  not  identify  any  previous  work  on  the  association  
between  autotaxin  and  bladder  cancer  however  studies  focusing  on  the  LPA  
signaling  pathway,  of  which  autotaxin  is  a  part,  and  in  particular  LPA  
receptors  and  bladder  cancer  have  been  reported.      
Lee  et  al.  (2007)  reported  that  the  LPA6  receptor  was  associated  with  familial  
bladder  cancer.  They  used  bladder  cancer  as  the  model  to  identify  clonal  
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genetic  factors  associated  with  growth  advantage.    This  then  allowed  them  to  
track  the  evolution  of  bladder  cancer  from  intra-­‐‑urothelial  precursor  lesions.  
They  found  that  the  LPA6  receptor,  which  is  associated  with  the  tumour  
suppressor  gene  RB1,  was  associated  with  loss  of  the  normal  variation  with  in  
a  cell  line  and  initial  development  of  neoplasia  in  situ.  
  
The  G  protein-­‐‑receptor  87  (GPR87),  which  has  been  identified  as  a  LPA  
receptor  (Tabata  et  al.  2007),  has  been  found  to  be  associated  with  bladder  
cancer.  Okazoe  et  al.  (2013)  found  that  GPR87  was  expressed  in  five  different  
human  bladder  cancer  cell  lines  and  that  by  silencing  GPR87  gene  expression  
cell  viability  was  reduced.  They  reported  GPR87  expression  was  positive  in  38  
(54%)  of  a  total  of  71  tumours.  Furthermore  they  found  that  patients  with  
GPR87  positive  tumours  had  a  shorter  recurrence  free  survival  than  those  
with  GPR87  negative  tumours  (p=0.010).  Multivariate  analysis  showed  that  
GPR87  staining  status  was  an  independent  prognostic  marker  for  intravesical  
recurrence  (p=0.041).    Progression  from  NMI  bladder  cancer  to  MI  cancer  was  
more  frequently  observed  among  the  patients  with  GPR87  positive  tumours  
although  this  was  not  statistically  significant  (p=0.056).  
  
Kataoka  et  al.  (2015)  reported  that  LPA  signaling  via  the  LPA1  receptor  
promoted  bladder  cancer  invasion.    They  found  LPA1  mRNA  was  
significantly  higher  in  muscle  invasive  bladder  cancer  samples  than  in  non-­‐‑
muscle  invasive  samples.  They  described  strong  LPA1  expression  on  the  cell  
membrane  in  muscle  invasive  samples.  Furthermore  they  found  that  LPA  
treatment  increased  T24  cell  invasion  while  treatment  with  a  LPA1  inhibitor  
lead  to  a  decrease  in  invasiveness.  They  also  reported  that  LPA  treatment  
increased  ROCK1  (a  serinethreonine  kinase  that  regulates  cell  differentiation  
and  migration)  expression  and  myosin  light  chain  phosphorylation,  both  
factors  thought  to  affect  cancer  development.  
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5.1.3   Drawback  of  Present  Work  
Inadequacies  of  the  present  study  considering  the  association  between  
autotaxin  expression  and  bladder  cancer  include  that  although  the  study  
number  was  reasonable  the  low  prevalence  of  autotaxin  expression  generally  
under  powered  the  ability  to  identify  change  in  bladder  cancer.  If  the  study  
was  to  be  repeated  it  would  be  worthwhile  performing  a  power  calculation  to  
establish  how  many  patient  samples  I  would  need  to  sufficiently  power  
analysis.  
The  aim  of  this  project  was  to  consider  the  association  between  autotaxin  and  
bladder  cancer.  Therefore,  there  was  no  intention  to  analyze  the  relation  
between  autotaxin  and  normal  bladder  tissue  however  this  would  be  an  
interesting  area  to  look  at  in  future  work  as  normal  bladder  would  serve  as  a  
good  control  group.    A  small  number  of  normal  bladder  specimens  were  
examined  in  this  study  but  it  is  possible  that  that  they  did  not  represent  truly  
‘normal’  bladder  mucosa.  Both  practically  and  ethically  it  is  very  difficult  to  
collect  histologically  normal  bladder  mucosa.  Even  ‘normal’  tissue  from  a  
bladder  with  cancer  is  likely  to  demonstrate  field  changes  so  therefore  cannot  
be  considered  to  be  completely  normal.  
  
A  further  inadequacy  of  the  current  study  is  that  the  analysis  does  not  allow  
me  to  analyze  if  the  effects  that  I  have  reported  is  an  effect  specific  to  
neoplastic  cancer  or  if  it  could  for  example  be  found  in  inflamed  bladder  
mucosa  also.  
  
5.1.4   Future  Work  
Future  work  would  involve  performing  a  power  calculation  initially  to  
determine  the  number  of  patients  needed  to  power  analysis  as  well  as  
including  normal  bladder  tissue  to  use  as  a  control.     
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5.2  Renal  cancer  
  
5.2.1  Main  Findings  
I  found  that  in  renal  cancer,  that  there  was  no  significant  association  between  
autotaxin  expression  and  survival  or  time  to  disease  progression.  
Multivariate  analysis  also  found  that  autotaxin  had  no  prognostic  significance  
in  relation  to  renal  cell  carcinoma  and  no  association  with  time  to  disease  
progression.  
I  did  however  show  that  the  high  level  expression  of  autotaxin  observed  on  
the  tumour-­‐‑associated  vasculature  was  not  apparent  in  the  blood  vessels  of  
matched  normal  renal  tissues.  Unfortunately,  the  number  of  matched  normal  
samples  was  too  small  to  allow  statistical  analysis.  
  
5.2.2   Previous  Work  
At  the  start  of  this  study  there  was  no  published  work  on  autotaxin  and  renal  
cancer  however  since  embarking  on  this  project  Su  et  al.  (2013)  reported  that  
altered  autotaxin  expression  was  detected  in  sunitinib-­‐‑treated  tumour  
vasculature  of  human  RCC  and  in  the  tumour  endothelial  cells  of  RCC  
xenograft  models  when  adapting  to  Sunitinib.      
In  the  current  study  autotaxin  expression  in  vessels  only  was  reported  as  
expression  was  found  to  be  negative  in  all  tumour  cases.  
Su  et  al.  (2013)  also  reported  that  autotaxin  and  LPA,  which  is  the  catalytic  
product  of  autotaxin,  were  both  involved  in  the  regulation  of  signaling  
pathways  in  RCC  in  vitro,  as  well  as  cell  motility.    They  found  that  by  using  
an  LPA1  antagonist  to  block  the  LPA  receptor  1  or  gene  silencing  of  LPA1  in  
RCC  cells  resulted  in  increased  LPA-­‐‑mediated  intracellular  signaling  and  
invasion  in  vitro.    The  LPA1  antagonist  also  reduced  RCC  tumourigenesis  in  
vivo.    Furthermore,  LPA1  antagonist  given  along  with  Sunitinib  was  found  to  
prolong  the  sensitivity  of  RCC  to  sunitinib  in  xenograft  models,  which  implies  
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that  autotaxin-­‐‑LPA  signaling  may  play  a  role  in  acquired  resistance  against  
Sunitinib  in  RCC.  
  
5.2.3   Drawback  of  Present  Work  
There  were  several  inadequacies  of  this  analysis.  The  cohort  of  59  patients  is  
too  small  to  detect  any  significant  associations  between  autotaxin  expression  
and  renal  cancer  with  confidence.  
The  cohort  comprised  patients  with  metastatic  renal  cell  carcinoma  who  were  
about  to  commence  treatment  with  Sunitinib.  Future  analysis  would  include  
renal  cell  carcinomas  samples  of  various  stages  taken  before,  as  well  as  after,  
treatment  had  commenced,  to  establish  what  effect  if  any  Sunitinib  had  on  
autotaxin  expression.  
There  were  also  too  few  histologically  normal  renal  tissue  samples  included  
to  allow  any  firm  conclusions  to  be  drawn.  Similarly  to  that  of  bladder  cancer  
collecting  normal  renal  tissue  is  problematic  both  practically  and  ethically.      
  
5.2.4   Future  Work  
Future  work  would  involve  expanding  the  cohort  number,  patients  with  
various  stages  of  the  disease,  and  having  a  cohort  of  normal  renal  tissue  to  act  
as  the  control.  
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5.3  Autotaxin  inhibitors  
  
Autotaxin  is  secreted  by  multiple  different  cancer  cells  types  and  this  
contributes  to  the  cells  invasive  properties  (Gotoh  et  al.  2012).  Ovarian  cancer  
cells  produce  LPA  at  high  levels  (Baker  at  al.  2002,  Sutphen  et  al.  2004).    
However  it  is  not  clear  whether  elevated  LPA  levels  that  result  from  secretion  
of  autotaxin  by  cancer  cells  could  be  used  as  a  marker  for  cancer.    Plasma  
autotaxin  itself  does  not  appear  to  be  cancer  specific  as  high  levels  have  been  
found  in  benign  conditions  such  as  liver  disease  (Nakagawa  et  al.  2011,  
Waranabe  et  al.  2007),  pregnancy  (Iwasawa  et  al.  2009)  and  cardiac  conditions  
(Kimura  et  al.  2010).  
Autotaxin  is  one  of  40  genes  that  have  been  found  to  be  up-­‐‑regulated  in  
highly  metastatic  cancers  (Euer  et  al.  2002).  Expression  of  autotaxin  in  mice  
resulted  in  mammary  intraepithelial  neoplasia,  invasive  and  metastatic  
tumours  (Liu  et  al.  2009).    LPA  was  found  to  result  in  the  chemo-­‐‑resistance  of  
ovarian  cancer  cells  to  cisplatin  and  adriamycin  (ES  at  al.  2009)  and  paclitaxel-­‐‑
induced  apoptosis  in  cancer  cells  inhibited  by  autotaxin  (Samadi  et  al.  2009).  
Overexpression  of  autotaxin  was  found  in  patients  with  recurrent  disease  
after  chemotherapy  treatment  (Jazaeri  et  al.  2005).  Gotoh  et  al.  (2012)  found  
that  autotaxin  was  a  potential  drug-­‐‑resistance  gene  in  ovarian  cancer  and  
Vidot  et  al.  (2010)  showed  that  by  inhibiting  autotaxin  it  was  possible  to  
increase  the  sensitivity  of  resistant  cancer  cells.  
Benesch  et  al.  (2014)  described  how  inhibition  of  autotaxin  delayed  breast  
tumour  growth  and  lung  metastases  in  mice.  They  proposed  that  by  reducing  
LPA  production  and  signaling  in  tumours  it  could  offer  a  new  approach  to  
halting  the  development  of  metastases  and  chemotherapy  and  radiotherapy  
resistance  (Brindley  et  al.  2013).      
Van  Meeteren  et  al.  (2005)  describe  LPA  as  having  an  inhibitory  feedback  
effect  on  autotaxin.  If  this  is  the  case  then  LPA  analogues  that  inhibit  
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autotaxin  without  activating  the  LPA  receptors  could  potentially  prevent  
cancer  proliferation  and  invasion.      
There  have  been  multiple  publications  describing  various  autotaxin  inhibitors  
over  the  last  few  years  and  other  therapeutics  targeting  the  autotaxin-­‐‑LPA-­‐‑
LPA  receptor  signaling  pathway.    These  inhibitors  come  in  a  variety  of  
structures  including  metal  chelators  such  as  Bithionol,  lipid-­‐‑based  inhibitors  
such  as  HA155,  and  small  molecule  inhibitors  such  as  H2L-­‐‑7905958.    
While  pharmaceutical  companies  all  over  the  world  compete  to  find  the  next  











     
	   112	   	  
References  
  
1. Office  for  National  Statistics.    Cancer  and  mortality  in  the  UK  2005-­‐‑
2007.  www.statistics.gov.uk.    
2. Abdollah  F,  Gandaglia  G,  Thuret  R,  Schmitges  J,  Tian  Z,  Jeldres  C,  
Passoni  NM,  Briganti  A,  Shariat  SF,  Perrotte  P,  Montorsi  F,  Karakiewic,  
PI,  Sun  M.  (2013).  "ʺIncidence,  survival  and  mortality  rates  of  stage-­‐‑
specific  bladder  cancer  in  United  States:  a  trend  analysis."ʺ  Cancer  
Epidemiol  37(3):  219-­‐‑225.  
3. Baker,  D.  L,  Morrison,  P,  Miller,  B,  Riely,  C.  A,  Tolley,  B,  Westermann,  
A.  M,  Bonfrer,  J.  M,  Bais,  E,  Moolenaar,  W.  H,Tigyi,  G.  Baker.  (2002).  
"ʺPlasma  lysophosphatidic  acid  concentration  and  ovarian  cancer."ʺ  
JAMA  287(23):  3081-­‐‑3082.  
4. Baker  DL,  Fujiwara  Y,  Pigg  KR,  Tsukahara  R,  Kobayashi  S,  Murofushi  
H,  Uchiyama  A,  Murakami-­‐‑Murofushi  K,  Koh,  E,  Bandle  R.  W,  Byun  H  
S,  Bittman  R,  Fan  D,  Murph  M,  Mills  GB,  Tigyi,  G.  (2006)  Carba  
analogs  of  cyclic  phosphatidic  acid  are  selective  inhibitors  of  autotaxin  
and  cancer  cell  invasion  and  metastasis.  Journal  of  Biological  
Chemistry  281:22786-­‐‑22793.    
5. Bellocco  R,  Pasquali  E,  Rota  M,  Bagnardi  V,  Tramacere  I,  Scotti  L,  
Pelucchi  C,  Boffetta  P,  Corrao  G,  La  Vecchia.  (2012).  "ʺAlcohol  drinking  
and  risk  of  renal  cell  carcinoma:  results  of  a  meta-­‐‑analysis."ʺ  Ann  Oncol  
23(9):  2235-­‐‑2244.  
6. Benesch  MG,  Tang  X,  Maeda  T,  Ohhata  A,  Zhao  YY,  Kok  BP,  Dewald  J,  
Hitt  M,  Curtis  JM,  McMullen  TP.  (2014).  "ʺInhibition  of  autotaxin  delays  
breast  tumor  growth  and  lung  metastasis  in  mice."ʺ  FASEB  J  28(6):  2655-­‐‑
2666.  
	   113	   	  
7. Benesch  MG,  Ko  YM,  McMullen  TP,  Brindley  DN.    (2014).  "ʺAutotaxin  
in  the  crosshairs:  taking  aim  at  cancer  and  other  inflammatory  
conditions."ʺ  FEBS  Lett  588(16):  2712-­‐‑2727.  
8. Botteman  MF,  Pashos  CL,  Redaelli,  A,  Laskin  B,  Hauser,  R.  (2003).  "ʺThe  
health  economics  of  bladder  cancer:  a  comprehensive  review  of  the  
published  literature."ʺ  Pharmacoeconomics  21(18):  1315-­‐‑1330.  
9. Bourgoin  SG  &  Zhao  C.  (2010)  Autotaxin  and  lysophospholipids  in  
rheumatoid  arthritis.  Curr  Opin  Investig  Drugs.  11(5):515-­‐‑26.  
10. Brindley  DN,  Lin  FT,  Tigyi  GJ.  (2013).  "ʺRole  of  the  autotaxin-­‐‑
lysophosphatidate  axis  in  cancer  resistance  to  chemotherapy  and  
radiotherapy."ʺ  Biochim  Biophys  Acta  1831(1):  74-­‐‑85.  
11. Cancer  Research  UK.  (2015)  (www.cancerresearchuk.org).  
12. Calle  EE  &  Kaaks  R.  (2004)  Overweight,  obesity  and  cancer:  
epidemiological  evidence  and  proposed  mechanisms.  Nat  Rev  Cancer.  
4  (8):579-­‐‑591.  PMID:15286738  
13. Carrizosa  DR,  Godley  PA  (2009)  Epidemiology  and  screening  of  renal  
cell  carcinoma.  Rini  BI  Campbell  SC  Renal  cell  carcinoma.  In  People’s  
Medical  Publishing  House  Shelton  (CT)  15-­‐‑24.  
14. Cardenas-­‐‑Turanzas  M,  Cooksley  C,  Pettaway  CA,  Sabichi  A,  Grossman  
HB,  Elting  L.  (2006).  "ʺComparative  outcomes  of  bladder  cancer."ʺ  Obstet  
Gynecol  108(1):  169-­‐‑175.  
15. Chow  WH,  Gridley  G,  Frumeni  JF,  Jarvholm,  B.  (2000)  Obesity,  
hypertension,  and  the  risk  of  kidney  cancer  in  men.  N  Engl  J  Med.  343  
(18):1305-­‐‑1311  2000  PMID:11058675  
16. Chrouser  K,  Leibovich  B,  Bergstralh  E,  Zincke  H,  Blute  M.  (2005)  
Bladder  cancer  risk  following  primary  and  adjuvant  external  beam  
radiation  for  prostate  cancer.  J  Urol.  174(1):107-­‐‑10.  
17. Clague,  J,  Lin  J,  Cassidy  A,  Matin  S,  Tannir  NM,  Tamboli  P,  Wood  CG,  
Wu  X.  (2009).  "ʺFamily  history  and  risk  of  renal  cell  carcinoma:  results  
	   114	   	  
from  a  case-­‐‑control  study  and  systematic  meta-­‐‑analysis."ʺ  Cancer  
Epidemiol  Biomarkers  Prev  18(3):  801-­‐‑807.  
18. Crawford,  J.  M.  (2008).  "ʺThe  origins  of  bladder  cancer."ʺ  Lab  Invest  
88(7):  686-­‐‑693.  
19. David  M,  Wannecq  E,  Descotes  F,  Jansen  S,  Deux  B,  Ribeiro  J,  Serre  
CM,  Gres  S,  Bendriss-­‐‑Vermare  N,  Bollen  M,  Saez  S,  Aoki  J,  Saulnier-­‐‑
Blache  JS,  Clezardin  P,  Peyruchaud  O.  (2010)  Cancer  cell  expression  of  
autotaxin  controls  bone  metastasis  formation  in  mouse  through  
lysophosphatidic  acid-­‐‑deprivation  of  osteoclasts.  PLoS  One.  5(3):c9741.  
20. DeCastro  GJ,  McKiernan  JM  (2008)  Epidemiology,  clinical  staging  and  
presentation  of  renal  cell  carcinoma.  Urol  Clin  North  Am.  35:581-­‐‑592  
PMID:18992612  
21. Divrik  RT,  Yildirim  U,  Zorlu  F,  Ozen  H.  (2006)  The  effect  of  repeat  
transurethral  resection  on  recurrences  and  progression  rates  in  patients  
with  T1  tumours  of  the  bladder  who  received  intravesical  mitomycin:  a  
prospective,  randomized  clinical  trial.  J  Urol.  175(5):1641-­‐‑4.  
22. Du  XL,  Lin  CC,  Johnson  NJ,  Altekruse  S.  (2011).  "ʺEffects  of  individual-­‐‑
level  socioeconomic  factors  on  racial  disparities  in  cancer  treatment  
and  survival:  findings  from  the  National  Longitudinal  Mortality  Study,  
1979-­‐‑2003."ʺ  Cancer  117(14):  3242-­‐‑3251.  
23. Durgam  GG,  Virag  T,  Walker  MD  Tsukahara  R,  Yasuda  S,  Liliom  K,  
van  Meeteren  LA,  Moolenaar  WH,  Wilke  N,  Siess  W,  Tigyi  G,  Miller  
DD.  (2005)  Synthesis,  structure-­‐‑activity  relationships,  and  biological  
evaluation  of  fatty  alcohol  phosphates  as  lysophosphatidic  acid  
receptor  ligands,  activators  of  PARgamma,  and  inhibitors  of  autotaxin.  
Journal  of  Medicinal  Chemistry  48:4919-­‐‑4930.  
24. E  S,  Lai  YJ,  Tsukahara  R,  Chen  CS,  Fujiwara  Y,  Yue  J,  Yu  JH,  Guo  H,  
Kihara  A,  Tigyi  G,  Lin  FT.  (2009).  "ʺLysophosphatidic  acid  2  receptor-­‐‑
	   115	   	  
mediated  supramolecular  complex  formation  regulates  its  
antiapoptotic  effect."ʺ  J  Biol  Chem  284(21):  14558-­‐‑14571.  
25. Epstein  JL,  Amin  MB,  Reuter  VR,  et  al.  (1998).  The  World  Health  
Organisation/International  Society  of  Urological  Pathology  consensus  
classification  of  urothelial  (transitional  cell)  neoplasms  of  the  urinary  
bladder.  Am  J  Surg  Pathol.  22(12):1435-­‐‑48.  
26. Euer  N,  Schwirzke  M,  Evtimova  V,  Burtscher  H,  Jarsch  M,  Tarin  D,  
Weidle  UH.  (2002).  "ʺIdentification  of  genes  associated  with  metastasis  
of  mammary  carcinoma  in  metastatic  versus  non-­‐‑metastatic  cell  lines."ʺ  
Anticancer  Res  22(2A):  733-­‐‑740.  
27. European  Association  of  Urology  Guidelines,  2012,  2013  &  2015.  
28. European  Network  of  Cancer  Registries.  Eurocim  version  4.0.  
European  incidence  database  V2.3,  730  entity  dictionary  (2001),  Lyon,  
2001.  
29. Ferlay  J,  Steliarova-­‐‑Foucher  E,  Lortet-­‐‑Tieulent  J,  Rosso  S,  Coebergh  JW,  
Comber  H,  Forman  D,  Bray  F.  (2013).  "ʺCancer  incidence  and  mortality  
patterns  in  Europe:  estimates  for  40  countries  in  2012."ʺ  Eur  J  Cancer  
49(6):  1374-­‐‑1403.  
30. Ferry  G,  Tellier  E,  Try  A,  Gres  S,  Naime  I,  Simon  MF,  Rodriguez  M,  
Boucher  J,  Tack  I,  Gesta  S,  Chomarat  P,  Dieu  M,  Raes  M,  Galizzi  JP,  
Valet  P,  Boutin  JA,  Saulnier-­‐‑Blache  JS.  (2003)  Autotaxin  is  released  
form  adipocytes,  catalyses  lysophosphatidic  acid  synthesis,  and  
activated  preadiopocyte  proliferation.  Up-­‐‑regulated  expression  with  
adipocyte  differentiation  and  obesity.  J  Biol  Chem.  278(20):18162-­‐‑9.  
31. Fotopoulou  S,  Oikonomou  N,  Grigorieva  E,  Nikitopoulou  I,  
Paparountas  T,  Thanassopoulou  A,  Zhao  Z,  Xu  Y,  Kontoyiannis  DL,  
Remboutsika  E.,  Aidinis  V.  (2010)  ATX  expression  and  LPA  signaling  
are  vital  for  the  development  of  the  nervous  system.  Dev  Biol.  339:451-­‐‑
464.  
	   116	   	  
32. Gago-­‐‑Dominguez  M,  Castelao  JE,  Yuan  JM,  Ross  RK,  Yu  MC.  (2002)  
Lipid  peroxidation:  a  novel  and  unifying  concept  of  the  etiology  of  
renal  cell  carcinoma  (United  States).  Cancer  Causes  Control.  13  (3):287-­‐‑
293  PMID:12020111  
33. Gotoh  M,  Fujiwara  Y,  Yue  J,  Liu  J,  Lee  S,  Fells  J,  Uchiyama  A,  
Murakami,  Murofushi  K,  Kennel  S,  Wall  J,  Patil  R,  Gupte  R,  Balazs  L,  
Miller  DD,  Tigyi  GJ.  (2012).  "ʺControlling  cancer  through  the  autotaxin-­‐‑
lysophosphatidic  acid  receptor  axis."ʺ  Biochem  Soc  Trans  40(1):  31-­‐‑36.  
34. Grimm  MO,  Steinhoff  Ch,  Simon  X,  Spiegelhalder  P,  Ackermann  R,  
Vogeli  T.  A.  (2003)  Effect  of  routine  repeat  transurethral  resection  for  
superficial  bladder  cancer:  a  long-­‐‑term  observational  study.  J  Urol.  
170:433-­‐‑7.    
35. Harrison  SM,  Reavill  C,  Brown  JT,  Cluderay  JE,  Crook  B,  et  al.  (2003)  
LPA1  receptor-­‐‑deficient  mice  have  phenotypic  changes  observed  in  
psychiatric  disease.  Mol  Cell  Neurosci.  24(4):1170-­‐‑9.  
36. Hashimoto  K,  Araki  K,  Osaki  M,  et  al.  (2004)  MCM2  and  Ki-­‐‑67  
expression  in  human  lung  adenocarcinoma:  prognosis  implications.  
Pathology.  71(4):193-­‐‑2000.  
37. Houben  AJS  and  Moolenaar  WH.  (2011)  Autotaxin  and  LPA  signaling  
in  cancer.  Cancer  Metastasis  Rev.  30:557-­‐‑565.  
38. Huang  Z,  Willett  WC,  Manson  JE,  Rosner  B,  Stampfer  MJ,  Speizer  FE,  
Colditz  GA.  (1998)  Body  weight,  weight  change,  and  risk  for  
hypertension  in  women.  Ann  Intern  Med.  128  (2):81-­‐‑88  PMID:9441586  
39. Inoue  Ma  L,  Aoki  J,  Chun  J,  Ueda  H.  (2008)  Autotaxin,  a  synthetic  
enzyme  of  lysophosphatidic  acid  (LPA),  mediates  the  induction  of  
nerve-­‐‑injured  neuropathic  pain.  Mol  Pain.  4:6.  
40. Inoue  M,  Xie  W,  Matsushita  Y,  Chun,  J.Aoki  J,  Ueda  H.  (2008)  
Lysophosphatidylcholine  induces  neuropathic  pain  through  n  action  of  
	   117	   	  
autotaxin  to  generate  lysophosphatidic  acid.  Neuroscience.  152(2):  296-­‐‑
8.  
41. Iwasawa  Y,  Fujii  T,  Nagamatsu  T,  Kawana  K,  Okudaira  S,  Miura  S,  
Matsumoto  J,  Tomio  A,  Hyodo  H,  Yamashita  T,  Oda  K,  Kozuma  S,  
Aoki  J,  Yatomi  Y,  Taketani,  Y.  (2009).  "ʺExpression  of  autotaxin,  an  
ectoenzyme  that  produces  lysophosphatidic  acid,  in  human  placenta."ʺ  
Am  J  Reprod  Immunol  62(2):  90-­‐‑95.  
42. Jansen  S,  Stefan  C,  Creemers  JW,  Waelkens  E,  Van  Eynde  A,  Stalmans  
W,  Bollen  M.  Proteolytic  maturation  and  activation  of  autotaxin  
(NPP2),  a  secreted  metastasis-­‐‑enhancing  lysophospholipase.  (2005)  J  
Cell  Sci.  118:  3081-­‐‑3089.  
43. Jazaeri  AA,  Awtrey  CS,  Chandramouli  GV,  Chuang  YE,  Khan  J,  
Sotiriou  C,  Aprelikova  O,  Yee  CJ,  Zorn  KK,  Birrer  MJ,  Barrett  JC,  Boyd  
J.  (2005).  "ʺGene  expression  profiles  associated  with  response  to  
chemotherapy  in  epithelial  ovarian  cancers."ʺ  Clin  Cancer  Res  11(17):  
6300-­‐‑6310.  
44. Kaldor  JM,  Day  NE,  Kittelmann  B,  Pettersson  F,  Langmark  F,  Pedersen  
D,  Prior  P,  Neal  F,  Karjalainen  S,  Bell,  J.  (1995).  "ʺBladder  tumours  
following  chemotherapy  and  radiotherapy  for  ovarian  cancer:  a  case-­‐‑
control  study."ʺ  Int  J  Cancer  63(1):  1-­‐‑6.  
45. Kantor,  A.  F.  (1977).  "ʺCurrent  concepts  in  the  epidemiology  and  
etiology  of  primary  renal  cell  carcinoma."ʺ  J  Urol  117(4):  415-­‐‑417.  
46. Kaplan  MH,  Kaplan  MH,  Smith  DI,  Sundick  RS.  (1993).  "ʺIdentification  
of  a  G  protein  coupled  receptor  induced  in  activated  T  cells."ʺ  J  
Immunol  151(2):  628-­‐‑636.  
47. Kasiske  B,  O’Donnell  M,  Keane  W.  (1991)  The  Zucker  rat  model  of  
obesity,  insulin  resistance,  hyperlipidemia  and  renal  injury.  
Hypertension.  19  (1  Suppl.):  110-­‐‑115.  
	   118	   	  
48. Kataoka  M,  Kataoka  M,  Ishibashi  K,  Kumagai  S,  Yanagida  T,  Aikawa  
K,  Chiba  H,  Kojima  Y.  (2015).  "ʺExpression  and  Function  of  LPA1  in  
Bladder  Cancer."ʺ  J  Urol  194(1):  238-­‐‑244.  
49. Kato  M,  Suzuki  T,  Suzuki  Y,  Terasawa  Y,  Sasano  H,  Arai  Y.  (2004).  
"ʺNatural  history  of  small  renal  cell  carcinoma:  evaluation  of  growth  
rate,  histological  grade,  cell  proliferation  and  apoptosis."ʺ  J  Urol  172(3):  
863-­‐‑866.  
50. Kimura  T,  Itoh  T,  Fusazaki  T,  Matsui  H,  Sugawara  S,  Ogino  Y,  Endo  H,  
Kobayashi  K,  Nakamura  M.  (2010).  "ʺLow-­‐‑density  lipoprotein-­‐‑
cholesterol/high-­‐‑density  lipoprotein-­‐‑cholesterol  ratio  predicts  lipid-­‐‑rich  
coronary  plaque  in  patients  with  coronary  artery  disease-­‐‑-­‐‑integrated-­‐‑
backscatter  intravascular  ultrasound  study."ʺ  Circ  J  74(7):  1392-­‐‑1398.  
51. Kufe  DW,  Pollock  RE,  Weichselbaum  RR,  et  al.,  editors.  Holland-­‐‑Frei  
Cancer  Medicine  6th  edition.  Hamilton  (ON):  BC  Decker;  2003.  
52. Landis  SH,  Murray  T,  Bolden  S,  Wingo  PA.  1999.  Cancer  statistics:  
1999.  CA  Cancer  J  Clin.  49:8-­‐‑31  PMID:10200775  
53. La  Vecchia  C,  Negri  E,  D’Avanzo  B,  Franceschi  S.  1990.  Smoking  and  
renal  cell  carcinoma.  Cancer  Res.  50:5231-­‐‑5233  2386932  
54. Lee  S,  Jeong,  J,  Majewski  T,  Scherer  SE,  Kim  MS,  Tuziak  T,  Tang  KS,  
Baggerly  K,  Grossman  HB,  Zhou  JH,  Shen  L,  Bondaruk  J,  Ahmed  SS,  
Samanta  S,  Spiess  P,  Wu  X,  Filipek  S,  McConkey  D,  Bar-­‐‑Eli  M,  Issa  JP,  
Benedict  F,  Czerniak  B.  (2007).  "ʺForerunner  genes  contiguous  to  RB1  
contribute  to  the  development  of  in  situ  neoplasia."ʺ  Proc  Natl  Acad  Sci  
U  S  A  104(34):  13732-­‐‑13737.  
55. Leibovich  BC,  Blute  ML,  Cheville  JC,  Lohse  CM,  Frank  I,  Kwon  ED,  
Weaver  AL,  Parker  AS,  Zincke,  H.  (2003).  "ʺPrediction  of  progression  
after  radical  nephrectomy  for  patients  with  clear  cell  renal  cell  
carcinoma:  a  stratification  tool  for  prospective  clinical  trials."ʺ  Cancer  
97(7):  1663-­‐‑1671.  
	   119	   	  
56. Lengauer  C,  Kinzler  KW,  Vogelstein  B.  (1998).  "ʺGenetic  instabilities  in  
human  cancers."ʺ  Nature  396(6712):  643-­‐‑649.  
57. Lindblad,  P.  (2004).  "ʺEpidemiology  of  renal  cell  carcinoma."ʺ  Scand  J  
Surg  93(2):  88-­‐‑96.  
58. Lipworth  L,  Tarone  RE,  McLaughlin  JK.  (2006)  The  epidemiology  of  
renal  cell  carcinoma.  J  Urol.  176:2353-­‐‑2358  PMID:17085101  
59. Lipworth  L,  Lipworth  L,  Tarone  RE,  McLaughlin,  J.  K.  (2006).  "ʺThe  
epidemiology  of  renal  cell  carcinoma."ʺ  J  Urol  176(6  Pt  1):  2353-­‐‑2358.  
60. Liu  S,  Umezu-­‐‑Goto  M,  Murph  M,  Lu  Y,  Liu  W,  Zhang  F,  Yu  S,  
Stephens  LC,  Cui  X,  Murrow  G,  Coombes  K,  Muller  W,  Hung  MC,  
Perou  CM,  Lee  AV,  Fang  X,  Mills  GB.  (2009).  "ʺExpression  of  autotaxin  
and  lysophosphatidic  acid  receptors  increases  mammary  
tumorigenesis,  invasion,  and  metastases."ʺ  Cancer  Cell  15(6):  539-­‐‑550.  
61. Lokeshwar  VB,  Habuchi  T,  Grossman  HB,  Murphy  WM,  Hautmann  
SH,  Hemstreet  GP  3rd,  Bono  AV,  Getzenberg  RH,  Goebell  P,  Schmitz-­‐‑
Drager  BJ,  Schalken  JA,  Frade  Y,  Marberger  M,  Messing  E,  Droller  MJ.  
(2005)  Bladder  tumour  markers  beyond  cytology:  international  
consensus  panel  on  bladder  tumour  markers.  Urology.  66:35-­‐‑63.  
62. Lopez-­‐‑Beltran,  A.  (2008).  "ʺBladder  cancer:  clinical  and  pathological  
profile."ʺ  Scand  J  Urol  Nephrol  Suppl(218):  95-­‐‑109.  
63. Mallofre  C.,  Castillo  M,  Morente  V,  Sole  M.  (2003).  
"ʺImmunohistochemical  expression  of  CK20,  p53,  and  Ki-­‐‑67  as  objective  
markers  of  urothelial  dysplasia."ʺ  Mod  Pathol  16(3):  187-­‐‑191.  
64. May  f,  Treiber  U,  Hartung  R,  Schwaibold  H.  (2003)  Significance  of  
random  bladder  biopsies  in  superficial  bladder  cancer.  Eur  Urol.  44:47-­‐‑
50.  
65. McDougal,  W.  Scott.  Campbell-­‐‑Walsh  Urology  Tenth  Edition  Review.  
Philadelphia,  PA:  Elsevier/Saunders,  2012.  
	   120	   	  
66. McGrath  M,  Michaud  DS,  De  Vivo  I.  (2006).  "ʺHormonal  and  
reproductive  factors  and  the  risk  of  bladder  cancer  in  women."ʺ  Am  J  
Epidemiol  163(3):  236-­‐‑244.  
67. McLaughlin  JK,  Lindblad  P,  Mellemgaard  A,  McCredie  M,  Mandel  JS,  
Schlehofer  B,  Pommer  W,  Adami  HO.  (1995)  International  renal  cell  
cancer  study:  I.  Tobacco  use.  Int  J  Cancer.  60:94-­‐‑198.  
68. Messing,E.M.,  Young,T.B.,  Hunt,V.B.,  Gilchrist,K.W.,  Newton,M.A.,  
Bram,L.L.,  Hisgen,W.J.,  Greenberg,E.B.,  Kuglitsch,M.E.,  and  
Wegenke,J.D.  (1995).  Comparison  of  bladder  cancer  outcome  in  men  
undergoing  haematuria  home  screening  versus  those  with  standard  
clinical  presentations.  Urology  45,  387-­‐‑396.    
69. Mills,  G.  B.  and  W.  H.  Moolenaar  (2003).  "ʺThe  emerging  role  of  
lysophosphatidic  acid  in  cancer."ʺ  Nat  Rev  Cancer  3(8):  582-­‐‑591.  
70. Motzer  RJ,  bukowski  RM,  Curtis  BD,  George  DJ,  Hudes  GR,  Redman  
BG,  Margolin  KA,  Merchan  JR,  Wilding  G,  Ginsberg  MS,  Bacik  J,  Kim  
ST,  Baum  CM,  Michaelson  MD.    (2006).  "ʺSunitinib  in  patients  with  
metastatic  renal  cell  carcinoma."ʺ  JAMA  295(21):  2516-­‐‑2524.  
71. Motzer  RJ,  Hutson  TE,  Tomczak  P,  Michaelson  MD,  Bukowski  RM,  
Oudard  S,  et  al.  (2009).  Overall  survival  and  updated  results  for  
Sunitinib  compared  with  interferon  alfa  in  patients  with  metastatic  
renal  cell  carcinoma.  J  Clin  Oncol.  1;27(22):3584-­‐‑90.  
[PubMed:19487381].  
72. Motzer,  R.  J.,  et  al.  (2015).  "ʺNivolumab  versus  Everolimus  in  Advanced  
Renal-­‐‑Cell  Carcinoma."ʺ  N  Engl  J  Med  373(19):  1803-­‐‑1813.  
73. Nakagawa  H,  Ikeda  H,  Nakamura  K,  Ohkawa  R,  Masuzaki  R,  Tateishi  
R,  Yoshida  H,  Watanabe  N,  Tejima  K,  Kume  Y,  Iwai  T,  Suzuki  A,  
Tomiya  T,  Inoue  Y,  Nishikawa  T,  Ohtomo  N,  Tanoue  Y,  Omata  M,  
Igarashi  K,  Aoki  J,  Koike  K,  Yatomi  Y.  (2011).  "ʺAutotaxin  as  a  novel  
serum  marker  of  liver  fibrosis."ʺ  Clin  Chim  Acta  412(13-­‐‑14):  1201-­‐‑1206.  
	   121	   	  
74. Nakamura  K,  Igarashi  K,  Ide  K,  Ohkawa  R,  Okubo  S,  Yokota  H,  
Masuda  A,  Oshima  N,  Takeuchi  T,  Nangaku  M,  Okudaira  S,  Arai  H,  
Ikeda  H,  Aoki  J.,  Yatomi  Y.  (2008)  Validation  of  an  autotaxin  enzyme  
immunoassay  in  human  serum  samples  nad  its  application  to  
hypoalbuminemia  differentiation.  Clin.  Chim.  Acta  388:51-­‐‑58.  
75. Okazoe  H,  Zhang  X,  Liu  D,  Shibuya  S,  Ueda  N,  Sugimoto  M,  and  
Kakehi  Y.  (2013)  “Expression  and  role  of  GPR87  in  urothelial  
carcinoma  of  the  bladder”.    Int.  J.  Mol.  Sci.  14:12367-­‐‑12379.  
76. Okudaira  S,  Yukiura  H,  Aoki  J.  (2012)  Biological  roles  of  
lysophosphatidic  signaling  through  its  production  of  autotaxin.  
Biochimie.  92  (6):698-­‐‑706.  
77. ONS.  2003.  Cancer  Statistics-­‐‑  Registrations  of  Cancer  Diagnosed  in  
2000.  London:  ONS.  
78. Palou  J,  Rodriguez-­‐‑Rubio  F,  Huguet  J,  Segarra  J,  Ribal  MJ,  Alcaraz  A,  
Villavicencio  H.  (2005).  "ʺMultivariate  analysis  of  clinical  parameters  of  
synchronous  primary  superficial  bladder  cancer  and  upper  urinary  
tract  tumor."ʺ  J  Urol  174(3):  859-­‐‑861;  discussion  861.  
79. Pantuck  AJ,  Zisman  A,  Belldegrun  A  (2001)  Biology  of  renal  cell  
carcinoma:  changing  concepts  in  classification  and  staging.  Semin  Urol  
Oncol.  19:72-­‐‑79.  PMID:11354536    
80. Pantuck  AJ,  Zisman  A,  Belldegrun  AS.  (2001)  The  changing  natural  
history  of  renal  cell  carcinoma.  J  Urol.  166:1611-­‐‑1623  PMID:11586189  
81. Patard  JJ,  Rodriguez  A,  Rioux-­‐‑Leclercq  N,  Guille  F,  Lobel,  B.  (2002).  
"ʺPrognostic  significance  of  the  mode  of  detection  in  renal  tumours."ʺ  
BJU  Int  90(4):  358-­‐‑363.  
82. Payne  H,  Adamson  A,  Bahl  A,  Borwell  J,  Dodds  D,  Heath  C,  Huddart  
R,  McMenemin  R,  Patel  P,  Peters  JL,  Thompson  A.  (2013).  "ʺChemical-­‐‑  
and  radiation-­‐‑induced  haemorrhagic  cystitis:  current  treatments  and  
challenges."ʺ  BJU  Int  112(7):  885-­‐‑897.  
	   122	   	  
83. Prout,  G.  R.  and  V.  F.  Marshall  (1956).  "ʺThe  prognosis  with  untreated  
bladder  tumors."ʺ  Cancer  9(3):  551-­‐‑558.  
84. Ramnath  N,  Hernandez  FJ,  Tan  DF,  et  al.  (2001).  MCM2  is  an  
independent  predictor  of  survival  in  patients  with  non-­‐‑small  cell  lung  
cancer.  J  Clin  Oncol.  19(22):4259-­‐‑66.  
85. Ravaud  A,  Wallerand  H,  Culine  S,  Bernhard  JC,  Fergelot  P,  Bensalah  K,  
Patard  JJ.  (2008).  "ʺUpdate  on  the  medical  treatment  of  metastatic  renal  
cell  carcinoma."ʺ  Eur  Urol  54(2):  315-­‐‑325.  
86. Redelman-­‐‑Sidi  G,  Glickman  MS  &  Bochner  BH.  (2014)  The  mechanism  
of  action  of  BCG  therapy  for  bladder  cancer—a  current  perspective.  
Nature  Reviews  Urology  11,  153–162  doi:10.1038/nrurol.2014.15  
87. Reynolds  GM,  Billingham  LJ,  Gray  LJ,  Flavell  JR,  Najafipour  S,  Crocker  
J,  Nelson  P,  Young  LS,  Murray,  P.  G.  (2002).  "ʺInterleukin  6  expression  
by  Hodgkin/Reed-­‐‑Sternberg  cells  is  associated  with  the  presence  of  'ʹB'ʹ  
symptoms  and  failure  to  achieve  complete  remission  in  patients  with  
advanced  Hodgkin'ʹs  disease."ʺ  Br  J  Haematol  118(1):  195-­‐‑201.  
88. Riley  GF,  Potosky  AL,  Lubitz  JD,  Kessler  LG.  (1995).  "ʺMedicare  
payments  from  diagnosis  to  death  for  elderly  cancer  patients  by  stage  
at  diagnosis."ʺ  Med  Care  33(8):  828-­‐‑841.  
89. Samadi  N,  Riley  GF,  Potosky  AL,  Lubitz  JD,  Kessler  LG.  (2009).  
"ʺAutotaxin  protects  MCF-­‐‑7  breast  cancer  and  MDA-­‐‑MB-­‐‑435  melanoma  
cells  against  Taxol-­‐‑induced  apoptosis."ʺ  Oncogene  28(7):  1028-­‐‑1039.  
90. Sangar  VK,  Ragavan  N,  Matanhelia  SS,  Watson  MW,  Blades  RA.  
(2005).  "ʺThe  economic  consequences  of  prostate  and  bladder  cancer  in  
the  UK."ʺ  BJU  Int  95(1):  59-­‐‑63.  
91. Sauter  G,  Algaba  F,  Amin  M  et  al.  Tumours  of  the  urinary  system:  non-­‐‑
invasive  urothelial  neoplasias.  In:  Eble  JN,  Sauter  G,  Epstein  JL,  
Sesterhenn  I,  eds.  WHO  classification  of  classification  of  tumours  of  the  
	   123	   	  
urinary  system  and  male  genital  organs.  Lyon:  IARCC  Press,  2004,  pp.29-­‐‑
34.  
92. Sedlakova  I,  Vavrova  J,  Tosner  J  &  Hanousek  L.  (2006)  
Lysophosphatidic  acid  in  ovarian  cancer  patients.  Ceska  Gynekol  71(4):  
312-­‐‑7.  
93. Sedlakova  I,  Vavrova  J,  Tosner  J  &  Hanousek  L.  (2008)  
Lysophosphatidic  acid:  an  ovarian  cancer  marker.  Eur  J  Gynaecol  
Oncol,  29(5):  511-­‐‑4.  
94. Schover,  L.  R.  (1987).  "ʺSexuality  and  fertility  in  urologic  cancer  
patients."ʺ  Cancer  60(3  Suppl):  553-­‐‑558.  
95. Scosyrev  E,  Noyes  K,  Feng  C,  Messing  E.  (2009).  "ʺSex  and  racial  
differences  in  bladder  cancer  presentation  and  mortality  in  the  US."ʺ  
Cancer  115(1):  68-­‐‑74.  
96. Sobin  LH,  Gospodariwicz  M,  Wittekind  C  (eds).  TNM  classification  of  
malignant  tumours.  UICC  International  Union  Against  Cancer.  7th  edn.  
Oxford:  Wiley-­‐‑Blackwell,  2009.  
97. Song  DY,  Song  S,  Song  Y,  Lee  JE.  (2012).  "ʺAlcohol  intake  and  renal  cell  
cancer  risk:  a  meta-­‐‑analysis."ʺ  Br  J  Cancer  106(11):  1881-­‐‑1890.  
98. Stenzl  A,  Hennenlotter  J,  Schilling  D.  (2008).  "ʺCan  we  still  afford  
bladder  cancer?"ʺ  Curr  Opin  Urol  18(5):  488-­‐‑492.  
99. Stenzl  A,  Burger  M,  Fradet  Y,  Mynderse  LA,  Soloway  MS,  Witjes  JA,  
Kriegmair  M,  Karl  A,  Shen  Y,  Grossman,  HB.  (2010)  
Hexaminolevulinate  guided  fluorescence  cystoscopy  reduces  
recurrence  in  patients  with  non-­‐‑muscle  invasive  bladder  cancer.  J  Urol  
184(5);  1907-­‐‑13.    
100. Stortelers  C,  Kerkhoven  R,  Moolenaar  W.  (2008).  "ʺMultiple  
actions  of  lysophosphatidic  acid  on  fibroblasts  revealed  by  
transcriptional  profiling."ʺ  BMC  Genomics  9:  387.  
	   124	   	  
101. Stracke  ML,  Krutzsch  HC,  Unsworth  EJ,  Arestad  A,  Cioce  V,  
Schiffmann  E.,  Liotta  LA.  (1992)    Idenitfication,  purification,  and  partial  
sequence  analysis  of  autotaxin,  a  novel  motility-­‐‑stimulating  protein.  J  
Biol  Chem.  267(4):2524-­‐‑9.    
102. Su  SC,  Hu  X,  Kenney  PA,  Merrill  MM,  Babaian  KN,  Zhang  XY,  
Maity  T,  Yang  SF,  Lin  X,  Wood  CG.  (2013).  "ʺAutotaxin-­‐‑
lysophosphatidic  acid  signaling  axis  mediates  tumorigenesis  and  
development  of  acquired  resistance  to  sunitinib  in  renal  cell  
carcinoma."ʺ  Clin  Cancer  Res  19(23):  6461-­‐‑6472.  
103. Sutphen  R,  Xu  Y,  Wilbanks  GD,  Fiorica  J,  Grendys  EC.  Jr,  
LaPolla  JP,  Arango  H,  Hoffman  MS,  Martino  M,  Wakeley  K,  Griffin  D,  
Blanco  RW,  Cantor  AB,  Xiao  YJ,  Krischer,  J.  P.  (2004).  
"ʺLysophospholipids  are  potential  biomarkers  of  ovarian  cancer."ʺ  
Cancer  Epidemiol  Biomarkers  Prev  13(7):  1185-­‐‑1191.  
104. Sylvester  RJ,  van  der  Meijden  Ap,  Lamm  DL.  (2002).  
"ʺIntravesical  bacillus  Calmette-­‐‑Guerin  reduces  the  risk  of  progression  
in  patients  with  superficial  bladder  cancer:  a  meta-­‐‑analysis  of  the  
published  results  of  randomized  clinical  trials."ʺ  J  Urol  168(5):  1964-­‐‑
1970.  
105. Sylvester  RJ,  Oosterlinck  W,  van  der  Meijden  AP.  (2004).  "ʺA  
single  immediate  postoperative  instillation  of  chemotherapy  decreases  
the  risk  of  recurrence  in  patients  with  stage  Ta  T1  bladder  cancer:  a  
meta-­‐‑analysis  of  published  results  of  randomized  clinical  trials."ʺ  J  Urol  
171(6  Pt  1):  2186-­‐‑2190,  quiz  2435.  
106. Tabata  K,  Baba  K,  Shiraishi  A,  Ito  M,  Fujita  N.  (2007)  “The  
orphan  GPCR  GPR87  was  orphanedized  and  shown  to  be  a  
lysophosphatidic  acid  receptor”.  Biochem.  Biophys.  Res.  Commun.  
363:861-­‐‑866.  
	   125	   	  
107. Tabuchi  S.  (2015)  The  autotaxin-­‐‑lysophosphatidic  acid-­‐‑
lysophosphatidic  acid  receptor  cascade:  proposal  of  a  novel  potential  
therapeutic  target  for  treating  glioblastoma  multiforme.  Lipids  in  
Health  and  Disease.  DOI  10.1186/s12944-­‐‑015-­‐‑0059-­‐‑5.  
108. Tania  M,  Khan  A,  Zhang  H,  Li  J,  Song  Y.  (2010)  Autotaxin:  A  
protein  with  two  faces.  Biochemical  and  Biophysical  Communications.  
401:  493-­‐‑497.    
109. Travis  LB,  Curtis  RE,  Glimelius  B,  Holowaty  EJ,  Van  Leeuwen  
FE,  Lynch  CF,  Hagenbeek  A,  Stovall  M,  Banks  PM,  Adami  J.  et  al.  
(1995).  "ʺBladder  and  kidney  cancer  following  cyclophosphamide  
therapy  for  non-­‐‑Hodgkin'ʹs  lymphoma."ʺ  J  Natl  Cancer  Inst  87(7):  524-­‐‑
530.  
110. Tsui  KH,  Shvarts  O,  Smith  RB,  Figlin  R,  de  Kernion  JB,  
Belldegrun,  A.  (2000).  "ʺRenal  cell  carcinoma:  prognostic  significance  of  
incidentally  detected  tumors."ʺ  J  Urol  163(2):  426-­‐‑430.  
111. Vaidya  A,  Soloway  MS,  Hawke  C,  Tiguert  R,  Civantos  F.  (2001).  
"ʺDe  novo  muscle  invasive  bladder  cancer:  is  there  a  change  in  trend?"ʺ  J  
Urol  165(1):  47-­‐‑50;  discussion  50.  
112. Van  Meeteren  LA,  Ruurs  P,  Christodoulou  E,  Goding  JW,  
Takakusa  H,  Kikuchi  K,  Perrakis  A,  Nagano  T,  Moolenaar  WH.    (2005)  
Inhibition  of  autotaxin  by  lysophosphatidic  acid  and  sphingosine  1-­‐‑
phospate.  Journal  of  Biological  Chemistry  280:21155-­‐‑21161.  
113. Vasdev  N,  Altal  Y,  Mafeld    S,  Wong    K,  Chadwick  D,  Gowda  
BD,  Mutton  A,  Nagarajan  S,  Bhatti  A.  (2014).  "ʺCan  the  Leibovich  score  
for  clear  cell  renal  cell  carcinoma  (ccRCC)  be  accurately  reported  by  a  
general  pathologist?"ʺ  BJU  Int  113(4):  581-­‐‑585.  
114. Vidot  S,  Witham  J,  Agarwal  R,  Greenhough  S,  Bamrah  HS,  Tigyi  
GJ,  Kaye  SB,  Richardson  A.  (2010).  "ʺAutotaxin  delays  apoptosis  
	   126	   	  
induced  by  carboplatin  in  ovarian  cancer  cells."ʺ  Cell  Signal  22(6):  926-­‐‑
935.  
115. Wallen  EM,  Pruthi  RS,  Joyce  GF,  Wise  M,  Urologic  Diseases  in  
America  Project  (2007)  Kidney  cancer.  J  Urol.  177:2006-­‐‑2019  
PMID:17509280  
116. Walsh,  D.  L.  and  S.  S.  Chang  (2009).  "ʺDilemmas  in  the  treatment  
of  urothelial  cancers  of  the  prostate."ʺ  Urol  Oncol  27(4):  352-­‐‑357.  
117. Watanabe  N,  Ikeda  H,  Nakamura  K,  Ohkawa  R,  Kume  Y,  Aoki  
J,  Hama  K,  Okudaira  S,  Tanaka  M,  Tomiya  T,  Yanase  M,  Tejima  K,  
Nishikawa  T,  Arai  M,  Arai  H,  Omata  M,  Fujiwara  K,  Yatomi,  Y.  (2007).  
"ʺBoth  plasma  lysophosphatidic  acid  and  serum  autotaxin  levels  are  
increased  in  chronic  hepatitis  C."ʺ  J  Clin  Gastroenterol  41(6):  616-­‐‑623.  
118. Wein  AJ,  Kavoussi  LR,  Novick  AC,  Partin  AW,  Peters  CA.  
(2012).  Campbell-­‐‑Walsh  Urology.  10th  Edition.  Philadelphia:  Elsevier  
Saunders.  
119. Wittekind  BJ,  Compton  CC,  Sobin  LH  (eds).  A  commentary  on  
Uniform  Use.  UICC  International  Union  against  cancer.  4th  edition.  
Wiley-­‐‑Blackwell.  P.  106-­‐‑106.  
120. Woldrich  JM,  Mallin  K,  Ritchey  J,  Carroll  PR,  Kane  CJ.  (2008)  
Sex  differences  in  renal  cell  cancer  presentation  and  survival:  an  
analysis  of  the  National  Cancer  Database,  1993–2004.  J  Urol.  179  
(5):1709-­‐‑1713  discussion  1713  PMID:18343430  
121. Wolpert  BJ,  Amr  S,  Ezzat  S,  Saleh  D,  Gouda  I,  Loay  I,  Hifnawy  
T,  Mikhail  NN,  Abdel-­‐‑Hamid  M,  Zhan  M,  Zheng  YL,  Squibb  K,  Abdel-­‐‑
Aziz  MA,  Zaghloul  M,  Khaled  H,  Loffredo  CA.  (2010).  "ʺEstrogen  
exposure  and  bladder  cancer  risk  in  Egyptian  women."ʺ  Maturitas  67(4):  
353-­‐‑357.  
	   127	   	  
122. Woolenaar  WH  &  Perrakis  A.  (2011)  Insights  into  autotaxin:  
how  to  produce  and  present  a  lipid  mediator.  Nature  Review  
Molecular  Cell  Biology  12:  674-­‐‑679.  
123. Yuan  JM,  Gago-­‐‑Dominguez  M,  Ross  RK,  Yu  MC.  (1998)  
Hypertension,  obesity  and  their  medications  in  relation  to  renal  cell  
carcinoma.  Br  J  Cancer.  77:1508-­‐‑1513  PMID:  9652770  
124. Zamora-­‐‑Ros,  R.,  et  al.  (2014).  "ʺFlavonoid  and  lignan  intake  in  
relation  to  bladder  cancer  risk  in  the  European  Prospective  
Investigation  into  Cancer  and  Nutrition  (EPIC)  study."ʺ  Br  J  Cancer  
111(9):  1870-­‐‑1880.  
125. Zeegers  MP,  Bryan  RT,  Langford  C,  Billingham  L,  Murray  P,  
Deshmukh  NS,  Hussain  S,  James  N,  Wallace  DM,  Cheng  KK.  (2010).  
"ʺThe  West  Midlands  Bladder  Cancer  Prognosis  Programme:  rationale  
and  design."ʺ  BJU  Int  105(6):  784-­‐‑788.  
126. Zhang  H,  Xu  X,  Gajewiak  J,  Tsukahara  R,  Fujiwara  Y,  Liu  J,  Fells  
JI,  Perygin  D,  Parrill  AL,  Tigyi  G,  Prestwich  GD.  (2009)  Dual  activity  
lysophosphatidic  acid  receptor  pan-­‐‑antagonist/autotaxin  inhibitor  
reduces  breast  cancer  cell  migration  in  vitro  and  causes  tumour  
regression  in  vivo.  Cancer  Research  69:5441-­‐‑5449.  
  
  
